IGT Selected in Public Tender to Provide Industry-Leading Digital Games in Norway

IGT PlayDigital’s PlayCasino Content and Aggregation Services Strengthen Norsk Tipping’s Game Portfolio

PR Newswire

LONDON, Nov. 19, 2020 /PRNewswire/ — International Game Technology PLC (“IGT”) (NYSE: IGT) announced today that IGT Global Services Limited (hereinafter “IGT”) has been awarded a tender by Norsk Tipping AS (“Norsk Tipping”), Norway’s state lottery operator and World Lottery Association member, to continue supplying its proprietary IGT PlayCasino content, its PlayRGS digital gaming platform, and the IGT Connect™ integration layer. As part of the award, which was the result of a competitive public procurement, IGT will also continue supplying best-in-class licensed third-party game content from sub-suppliers NetEnt Malta Limited (“NetEnt”) and ELKAB Studios AB (“Elk”).

“IGT PlayDigital’s solutions enable Norsk Tipping to provide its players with highly engaging online content, including IGT’s top-performing PlayCasino games,” said Hans Erland Ringsvold, Head of Gaming Operations at Norsk Tipping“When we first entered the iCasino market in 2014, IGT was our sole digital supplier, and since then has been fundamental to our program’s success. We’re pleased to continue this partnership by delivering IGT’s and select third-party content to our players.”

“IGT’s best-in-class titles and seamless content aggregation technology ensure that Norsk Tipping can continue to offer their players the widest and most popular selection of entertaining digital games,” said Enrico Drago, IGT Senior Vice President, PlayDigital“Adding IGT’s and its sub-suppliers’ growing stable of popular titles for Norsk Tipping also furthers our goal of delivering unrivalled gaming experiences that engage players.”

IGT is one of three primary content suppliers selected by Norsk Tipping as part of the public procurement. The agreement, which allows IGT to offer content to Norsk Tipping over a period of three years with an option for Norsk Tipping to extend for one year, is effective in February 2021 and includes the provision of IGT’s proprietary PlayCasino games, in addition to supplying licensed NetEnt Group (including Red Tiger Gaming) and Elk content. As part of the agreement, Norsk Tipping can choose to keep games in operation for up to an additional four years after the agreement has expired.

Norsk Tipping has been a valued IGT customer since 2012, when IGT was selected as the sole supplier for the launch of legal digital gaming in Norway. In 2017, IGT was again awarded a competitive tender to provide Norsk Tipping with IGT proprietary PlayCasino content, as well as licensed content from third-party sub-suppliers, and its PlayRGS digital gaming platform and IGT Connect integration layer. IGT has also supplied Norsk Tipping with its digital bingo platform since 2014, which was re-awarded to IGT in a public tender in 2018.  

IGT PlayDigital’s PlayRGS solution powers sites for more than 100 customers around the globe for both lottery and commercial operators. In addition to Norsk Tipping, IGT supplies its PlayRGS solution to World Lottery Association (WLA) customers in Europe including Veikkaus in Finland, Svenska Spel in Sweden, Loterie Nationale in Belgium, and Lottomatica in Italy, and provides PlayRGS content to Danske Spil in Denmark. IGT also supplies PlayRGS to Lotto New Zealand and to Canadian members Loto Québec, Ontario Lottery and Gaming Corporation, the British Columbia Lottery Corporation, the Alberta Gaming, Liquor and Cannabis Commission, and the Atlantic Lottery Corporation.

For more information, visit IGT.com, or go to Facebook at facebook.com/IGT, follow us on Twitter at twitter.com/IGTnews, or watch IGT videos on YouTube at youtube.com/igt. 

About IGT
IGT (NYSE:IGT) is the global leader in gaming. We deliver entertaining and responsible gaming experiences for players across all channels and regulated segments, from Gaming Machines and Lotteries to Sports Betting and Digital. Leveraging a wealth of compelling content, substantial investment in innovation, player insights, operational expertise, and leading-edge technology, our solutions deliver unrivaled gaming experiences that engage players and drive growth. We have a well-established local presence and relationships with governments and regulators in more than 100 countries around the world, and create value by adhering to the highest standards of service, integrity, and responsibility. IGT has approximately 11,000 employees. For more information, please visit www.igt.com.

Contact:

Phil O’Shaughnessy, Global Communications, toll free in U.S./Canada +1 (844) IGT-7452; outside U.S./Canada +1 (401) 392-7452
Francesco Luti, +39 3485475493; for Italian media inquiries
James Hurley, Investor Relations, +1 (401) 392-7190
Rhonda Whittaker, Global Communications, +1 (506) 878-6471

© 2020 IGT

The trademarks and/or service marks used herein are either trademarks or registered trademarks of IGT, its affiliates or its licensors.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/igt-selected-in-public-tender-to-provide-industry-leading-digital-games-in-norway-301176457.html

SOURCE International Game Technology PLC

Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine

Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine

LORBRENA treatment resulted in 72% reduction in risk of progression or death

Data also show secondary endpoint of intra-cranial response substantially improved with LORBRENA

NEW YORK–(BUSINESS WIRE)–
Pfizer Inc. (NYSE:PFE) today announced results from the Phase 3 CROWN trial of LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) were published online ahead of print in the New England Journal of Medicine. At a planned interim analysis, LORBRENA treatment resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) according to blinded independent central review (BICR), the primary endpoint, compared to XALKORI (HR 0.28: 95% CI, 0.19 to 0.41; p<0.001), corresponding to a 72% reduction in the risk of progression or death. The trial is continuing for the secondary endpoint of overall survival (OS), which was not mature at the time of analysis.

“For nearly a decade, we have been committed to transforming the treatment of non-small cell lung cancer through the development of innovative medicines like LORBRENA, a third-generation ALK-inhibitor specifically developed to inhibit the most common tumor mutations that drive resistance to current medications and to address brain metastases,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “The prolonged progression-free survival data and intracranial responses seen in the CROWN trial highlight the potential role for LORBRENA to significantly improve outcomes for people with previously untreated ALK-positive advanced NSCLC and we are pleased that these data will be reviewed as part of the FDA’s Real-Time Oncology Review (RTOR) pilot program.”

As a secondary endpoint, the confirmed objective response rate (ORR) was 76% (95% CI, 68 to 83) with LORBRENA and 58% (95% CI, 49 to 66) with XALKORI. Additionally, LORBRENA showed increased intracranial activity compared with XALKORI. In the LORBRENA arm, 96% (95% CI, 91 to 98) of people were without central nervous system (CNS) progression at 12 months compared to 60% (95% CI, 49 to 69) in the XALKORI arm (HR 0.07: 95% CI, 0.03 to 0.17). In people presenting with measurable brain metastases (n=30), the intracranial ORR was 82% (95% CI, 57 to 96, n=14) with LORBRENA and 23% (95% CI, 5 to 54, n=3) with XALKORI; intracranial complete response rates of 71% and 8% were seen in each arm, respectively.

“Biomarker-driven medicines have improved outcomes for people living with ALK-positive non-small cell lung cancer, but innovative therapies are still needed to delay disease progression,” said Benjamin Solomon, M.D., Department of Medical Oncology, Peter MacCallum Cancer Centre. “The results from the CROWN trial demonstrate that LORBRENA has the potential to be a practice-changing, first-line option, and we thank the many people and their families who participated in this trial.”

In this trial, adverse events (AEs) occurring in >20% of patients treated with LORBRENA were hypercholesterolemia (70%), hypertriglyceridemia (64%), edema (55%), weight increase (38%), peripheral neuropathy (34%), cognitive effects (21%), and diarrhea (21%). Grade 3 or 4 AEs occurred in 72% of people treated with LORBRENA and 56% of people treated with XALKORI. The most common Grade 3 or 4 AEs for LORBRENA were hypertriglyceridemia (20%), increased weight (17%), hypercholesterolemia (16%), and hypertension (10%). Adverse events leading to permanent treatment discontinuation occurred in 7% of people treated with LORBRENA and 9% of people treated with XALKORI.

CROWN is a global, Phase 3, randomized, open-label, parallel 2-arm trial in which 296 people with previously untreated ALK-positive advanced NSCLC were randomized 1:1 to receive LORBRENA monotherapy (n=149) or XALKORI monotherapy (n=147). The primary endpoint of the CROWN trial is PFS based on BICR. Secondary endpoints include PFS based on investigator’s assessment, OS, ORR, intracranial objective response, and safety.

In 2018, the Food and Drug Administration (FDA) approved LORBRENA for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. This indication is approved under accelerated approval based on tumor response rate and duration of response. CROWN is the confirmatory trial for the conversion to full approval. Based on the positive outcome of the CROWN trial, the data will be reviewed under the FDA’s Real Time Oncology Review pilot program and will be shared with other health authorities to seek approval for an indication that includes previously untreated ALK-positive advanced NSCLC.

Lung cancer is the number one cause of cancer-related death around the world.1 NSCLC accounts for approximately 80-85% of lung cancers,2 with ALK-positive tumors occurring in about 3-5% of NSCLC cases.3 In 2020, an estimated 13,000 new cases of ALK-positive NSCLC are expected to be diagnosed in the G7.4

About LORBRENA® (lorlatinib)

LORBRENA is a tyrosine kinase inhibitor (TKI) that has been shown to be highly active in preclinical lung cancer models harboring chromosomal rearrangements of ALK. LORBRENA was specifically developed to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood brain barrier. LORBRENA is approved in the U.S. for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on:

  • crizotinib and at least one other ALK inhibitor for metastatic disease; or
  • alectinib as the first ALK inhibitor therapy for metastatic disease; or
  • ceritinib as the first ALK inhibitor therapy for metastatic disease.
  • This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

The full prescribing information for LORBRENA can be found here.

IMPORTANT LORBRENA® (lorlatinib) SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION

Contraindications: LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity.

Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers: Severe hepatotoxicity occurred in 10 of 12 healthy subjects receiving a single dose of LORBRENA with multiple daily doses of rifampin, a strong CYP3A inducer. Grade 4 ALT or AST elevations occurred in 50% of subjects, Grade 3 in 33% of subjects, and Grade 2 in 8% of subjects. ALT or AST elevations occurred within 3 days and returned to within normal limits after a median of 15 days (7 to 34 days); median time to recovery in subjects with Grade 3 or 4 or Grade 2 ALT or AST elevations was 18 days and 7 days, respectively. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA. Avoid concomitant use of LORBRENA with moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers cannot be avoided, monitor AST, ALT, and bilirubin 48 hours after initiating LORBRENA and at least 3 times during the first week after initiating LORBRENA. Depending upon the relative importance of each drug, discontinue LORBRENA or the CYP3A inducer for persistent Grade 2 or higher hepatotoxicity.

Central Nervous System (CNS) Effects: A broad spectrum of CNS effects can occur; overall, CNS effects occurred in 54% of 332 patients receiving LORBRENA. These included seizures (3%, sometimes in conjunction with other neurologic findings), hallucinations (7%; 0.6% severe [Grade 3 or 4]), and changes in cognitive function (29%; 2.1% severe), mood (including suicidal ideation) (24%; 1.8% severe), speech (14%; 0.3% severe), mental status (2.1%; 1.8% severe), and sleep (10%). Median time to first onset of any CNS effect was 1.2 months (1 day to 1.7 years). Overall, 1.5% and 9% of patients required permanent or temporary discontinuation of LORBRENA, respectively, for a CNS effect; 8% required dose reduction. Withhold and resume at same or reduced dose or permanently discontinue based on severity.

Hyperlipidemia: Increases in serum cholesterol and triglycerides can occur. Grade 3 or 4 elevations in total cholesterol occurred in 17% and Grade 3 or 4 elevations in triglycerides occurred in 17% of the 332 patients who received LORBRENA. Median time to onset was 15 days for both hypercholesterolemia and hypertriglyceridemia. Approximately 7% and 3% of patients required temporary discontinuation or dose reduction of LORBRENA, respectively, for elevations in cholesterol and in triglycerides. Eighty percent of patients required initiation of lipid-lowering medications, with a median time to onset of start of such medications of 21 days. Initiate or increase the dose of lipid-lowering agents in patients with hyperlipidemia. Monitor serum cholesterol and triglycerides before initiating LORBRENA, 1 and 2 months after initiating LORBRENA, and periodically thereafter. Withhold and resume at same dose for the first occurrence; resume at same or reduced dose of LORBRENA for recurrence based on severity.

Atrioventricular (AV) Block: PR interval prolongation and AV block can occur. In 295 patients who received LORBRENA at a dose of 100 mg orally once daily and who had a baseline electrocardiography (ECG), 1% experienced AV block and 0.3% experienced Grade 3 AV block and underwent pacemaker placement. Monitor ECG prior to initiating LORBRENA and periodically thereafter. Withhold and resume at reduced or same dose in patients who undergo pacemaker placement. Permanently discontinue for recurrence in patients without a pacemaker.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe or life-threatening pulmonary adverse reactions consistent with ILD/pneumonitis can occur. ILD/pneumonitis occurred in 1.5% of patients, including Grade 3 or 4 ILD/pneumonitis in 1.2% of patients. One patient (0.3%) discontinued LORBRENA for ILD/pneumonitis. Promptly investigate for ILD/pneumonitis in any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis. Immediately withhold LORBRENA in patients with suspected ILD/pneumonitis. Permanently discontinue LORBRENA for treatment-related ILD/pneumonitis of any severity.

Embryo-fetal Toxicity: LORBRENA can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with LORBRENA and for 3 months after the final dose.

Adverse Reactions: Serious adverse reactions occurred in 32% of the 295 patients; the most frequently reported serious adverse reactions were pneumonia (3.4%), dyspnea (2.7%), pyrexia (2%), mental status changes (1.4%), and respiratory failure (1.4%). Fatal adverse reactions occurred in 2.7% of patients and included pneumonia (0.7%), myocardial infarction (0.7%), acute pulmonary edema (0.3%), embolism (0.3%), peripheral artery occlusion (0.3%), and respiratory distress (0.3%). The most common (≥20%) adverse reactions were (all Grades; Grade 3 or 4): edema (57%; 3.1%), peripheral neuropathy (47%; 2.7%), cognitive effects (27%; 2.0%), dyspnea (27%; 5.4%), fatigue (26%; 0.3%), weight gain (24%; 4.4%), arthralgia (23%; 0.7%), mood effects (23%; 1.7%), and diarrhea (22%; 0.7%); the most common (≥20%) laboratory abnormalities were (all Grades; Grade 3 or 4): hypercholesterolemia (96%; 18%), hypertriglyceridemia (90%; 18%), anemia (52%; 4.8%), hyperglycemia (52%; 5%), increased AST (37%; 2.1%), hypoalbuminemia (33%; 1.0%), increased ALT (28%; 2.1%), increased lipase (24%; 10%), and increased alkaline phosphatase (24%; 1.0%).

Drug Interactions: LORBRENA is contraindicated in patients taking strong CYP3A inducers. Avoid concomitant use with moderate CYP3A inducers and strong CYP3A inhibitors. If concomitant use of moderate CYP3A inducers cannot be avoided, monitor ALT, AST, and bilirubin as recommended. If concomitant use with a strong CYP3A inhibitor cannot be avoided, reduce the LORBRENA dose as recommended. Avoid concomitant use of LORBRENA with CYP3A substrates and P-gp substrates, which may reduce the efficacy of these substrates.

Lactation: Because of the potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment with LORBRENA and for 7 days after the final dose.

Hepatic Impairment: No dose adjustment is recommended for patients with mild hepatic impairment. The recommended dose of LORBRENA has not been established for patients with moderate or severe hepatic impairment.

Renal Impairment: No dose adjustment is recommended for patients with mild or moderate renal impairment. The recommended dose of LORBRENA has not been established for patients with severe renal impairment.

About XALKORI® (crizotinib)

XALKORI is a TKI indicated for the treatment of patients with metastatic NSCLC whose tumors are ALK- or ROS1-positive as detected by an FDA-approved test. XALKORI has received approval for patients with ALK-positive NSCLC in more than 90 countries including Australia, Canada, China, Japan, South Korea and the European Union. XALKORI is also approved for ROS1-positive NSCLC in more than 60 countries.

The full prescribing information for XALKORI can be found here.

IMPORTANT XALKORI® (crizotinib) SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION

Hepatotoxicity: Drug-induced hepatotoxicity with fatal outcome occurred in 0.1% of patients treated with XALKORI across clinical trials (n=1719). Increased transaminases generally occurred within the first 2 months. Monitor liver function tests, including ALT, AST, and total bilirubin, every 2 weeks during the first 2 months of treatment, then once a month, and as clinically indicated, with more frequent repeat testing for increased liver transaminases, alkaline phosphatase, or total bilirubin in patients who develop increased transaminases. Permanently discontinue for ALT/AST elevation >3 times ULN with concurrent total bilirubin elevation >1.5 times ULN (in the absence of cholestasis or hemolysis); otherwise, temporarily suspend and dose-reduce XALKORI as indicated.

Interstitial Lung Disease/Pneumonitis: Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur. Across clinical trials (n=1719), 2.9% of XALKORI-treated patients had any grade ILD, 1.0% had Grade 3/4, and 0.5% had fatal ILD. ILD generally occurred within 3 months after initiation of treatment. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Exclude other potential causes and permanently discontinue XALKORI in patients with drug-related ILD/pneumonitis.

QT Interval Prolongation: QTc prolongation can occur. Across clinical trials (n=1616), 2.1% of patients had QTcF (corrected QT by the Fridericia method) ≥500 ms and 5% of 1582 patients had an increase from baseline QTcF ≥60 ms by automated machine-read evaluation of ECGs. Avoid use in patients with congenital long QT syndrome. Monitor ECGs and electrolytes in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that prolong the QT interval. Permanently discontinue XALKORI in patients who develop QTc >500 ms or ≥60 ms change from baseline with Torsade de pointes, polymorphic ventricular tachycardia, or signs/symptoms of serious arrhythmia. Withhold XALKORI in patients who develop QTc >500 ms on at least 2 separate ECGs until recovery to a QTc ≤480 ms, then resume at next lower dosage.

Bradycardia: Symptomatic bradycardia can occur. Across clinical trials, bradycardia occurred in 13% of patients treated with XALKORI (n=1719). Avoid use in combination with other medications known to cause bradycardia. Monitor heart rate and blood pressure regularly. If bradycardia occurs, re-evaluate for the use of concomitant medications known to cause bradycardia. Permanently discontinue for life-threatening bradycardia due to XALKORI; however, if associated with concomitant medications known to cause bradycardia or hypotension, hold XALKORI until recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If concomitant medications can be adjusted or discontinued, restart XALKORI at 250 mg once daily with frequent monitoring.

Severe Visual Loss: Across clinical trials, the incidence of Grade 4 visual field defect with vision loss was 0.2% of 1719 patients. Discontinue XALKORI in patients with new onset of severe visual loss (best corrected vision less than 20/200 in one or both eyes). Perform an ophthalmological evaluation. There is insufficient information to characterize the risks of resumption of XALKORI in patients with a severe visual loss; a decision to resume should consider the potential benefits to the patient.

Vision Disorders: Most commonly visual impairment, photopsia, blurred vision or vitreous floaters, occurred in 63% of 1719 patients. The majority (95%) of these patients had Grade 1 visual adverse reactions. 0.8% of patients had Grade 3 and 0.2% had Grade 4 visual impairment. The majority of patients on the XALKORI arms in Studies 1 and 2 (>50%) reported visual disturbances which occurred at a frequency of 4-7 days each week, lasted up to 1 minute, and had mild or no impact on daily activities.

Embryo-Fetal Toxicity: XALKORI can cause fetal harm when administered to a pregnant woman. Advise of the potential risk to the fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for at least 45 days (females) or 90 days (males) respectively, following the final dose of XALKORI.

ROS1-positive Metastatic NSCLC: Safety was evaluated in 50 patients with ROS1-positive metastatic NSCLC from a single-arm study, and was generally consistent with the safety profile of XALKORI evaluated in patients with ALK-positive metastatic NSCLC. Vision disorders occurred in 92% of patients in the ROS1 study; 90% of patients had Grade 1 vision disorders and 2% had Grade 2.

Adverse Reactions: Safety was evaluated in a phase 3 study in previously untreated patients with ALK-positive metastatic NSCLC randomized to XALKORI (n=171) or chemotherapy (n=169). Serious adverse events were reported in 34% of patients treated with XALKORI, the most frequent were dyspnea (4.1%) and pulmonary embolism (2.9%). Fatal adverse events in XALKORI-treated patients occurred in 2.3% of patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis. Common adverse reactions (all grades) occurring in ≥25% and more commonly (≥5%) in patients treated with XALKORI vs chemotherapy were vision disorder (71% vs 10%), diarrhea (61% vs 13%), edema (49% vs 12%), vomiting (46% vs 36%), constipation (43% vs 30%), upper respiratory infection (32% vs 12%), dysgeusia (26% vs 5%), and abdominal pain (26% vs 12%). Grade 3/4 reactions occurring at a ≥2% higher incidence with XALKORI vs chemotherapy were QT prolongation (2% vs 0%), esophagitis (2% vs 0%), and constipation (2% vs 0%). In patients treated with XALKORI vs chemotherapy, the following occurred: elevation of ALT (any grade [79% vs 33%] or Grade 3/4 [15% vs 2%]); elevation of AST (any grade [66% vs 28%] or Grade 3/4 [8% vs 1%]); neutropenia (any grade [52% vs 59%] or Grade 3/4 [11% vs 16%]); lymphopenia (any grade [48% vs 53%] or Grade 3/4 [7% vs 13%]); hypophosphatemia (any grade [32% vs 21%] or Grade 3/4 [10% vs 6%]). In patients treated with XALKORI vs chemotherapy, renal cysts occurred (5% vs 1%). Nausea (56%), decreased appetite (30%), fatigue (29%), and neuropathy (21%) also occurred in patients taking XALKORI.

Drug Interactions: Use caution with concomitant use of moderate CYP3A inhibitors. Avoid grapefruit or grapefruit juice which may increase plasma concentrations of crizotinib. Avoid concomitant use of strong CYP3A inducers and inhibitors. Avoid concomitant use of CYP3A substrates where minimal concentration changes may lead to serious adverse reactions. If concomitant use of XALKORI is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling.

Lactation: Because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with XALKORI and for 45 days after the final dose.

Hepatic Impairment: Crizotinib concentrations increased in patients with pre-existing moderate (any AST and total bilirubin >1.5x ULN and ≤3x ULN) or severe (any AST and total bilirubin >3x ULN) hepatic impairment. Reduce XALKORI dosage in patients with moderate or severe hepatic impairment. The recommended dose of XALKORI in patients with pre-existing moderate hepatic impairment is 200 mg orally twice daily or with pre-existing severe hepatic impairment is 250 mg orally once daily.

Renal Impairment: Decreases in estimated glomerular filtration rate occurred in patients treated with XALKORI. Administer XALKORI at a starting dose of 250 mg taken orally once daily in patients with severe renal impairment (CLcr <30 mL/min) not requiring dialysis.

About Pfizer Oncology

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 23 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.

Pfizer Inc.: Breakthroughs that change patients’ lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of November 19, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about LORBRENA® (lorlatinib), including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of LORBRENA; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications may be filed in any additional jurisdictions for LORBRENA for treatment of patients with ALK-positive metastatic non-small cell lung cancer or in any jurisdictions for any other potential indications for LORBRENA; whether and when any such other applications may be approved by regulatory authorities, which will depend on a myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether such product candidate will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of LORBRENA; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

__________________

1 World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: Lung fact sheet. http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed November 2020.

2 American Cancer Society. What is lung cancer? https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed November 2020.

3 Garber K. ALK, lung cancer, and personalized therapy: portent of the future? J Natl Cancer Inst. 2010;102:672-675.

4 Decision Resource Group, Kantar Health.

Pfizer Media Contact:

Steve Danehy

212-733-1538

[email protected]

Pfizer Investor Contact:

Bryan Dunn

212-733-8917

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

BJ’s Wholesale Club Holdings, Inc. Announces Record Third Quarter Fiscal 2020 Results

BJ’s Wholesale Club Holdings, Inc. Announces Record Third Quarter Fiscal 2020 Results

  • Comparable club sales, excluding gasoline sales, increased by 18.5%, including digitally enabled sales growth of approximately 200% for the third quarter of fiscal 2020.
  • Income from continuing operations increased by 122.6% year-over-year to $122.9 million, for the third quarter of fiscal 2020.
  • Adjusted EBITDA increased by 57.1% year-over-year to $242.2 million, for the third quarter of fiscal 2020.
  • Earnings per diluted share of $0.88, reflects a 120.0% year-over-year growth.
  • Adjusted earnings per diluted share of $0.92, reflects 124.4% year-over-year growth.
  • Net cash provided by operating activities was $802.0 million and free cash flow was $675.1 million, for the first nine months of fiscal 2020.

WESTBOROUGH, Mass.–(BUSINESS WIRE)–
BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) (the “Company”) today announced its financial results for the thirteen and thirty-nine weeks ended October 31, 2020.

“The third quarter was another remarkable quarter with robust comp growth, significant market share gains and record profitability. As we look ahead, we are confident our business will continue to thrive given the structural shift in consumer behavior, our market share gains and our strategic investments in digital capabilities, membership, assortment, marketing and geographic expansion,” said Lee Delaney, President and Chief Executive Officer, BJ’s Wholesale Club. “Our team members across our business are working hard to execute at the highest standards and meet our members’ increased demand for our products and services. We remain grateful for their continued dedication and hard work in helping us drive industry-leading results.”

Key Measures for the Thirteen Weeks Ended October 31, 2020 (Third Quarter of Fiscal 2020) and for the Thirty-Nine Weeks Ended October 31, 2020 (First Nine Months of Fiscal 2020):

BJ’S WHOLESALE CLUB HOLDINGS, INC.

 

 

 

 

 

 

 

 

(Amounts in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13 Weeks Ended

 

13 Weeks Ended

 

 

 

39 Weeks Ended

 

39 Weeks Ended

 

 

 

 

October 31, 2020

 

November 2, 2019

 

% Growth

 

October 31, 2020

 

November 2, 2019

 

% Growth

Net sales

 

$

3,646,723

 

 

$

3,152,887

 

 

15.7

%

 

$

11,236,403

 

 

$

9,493,795

 

 

18.4

%

Membership fee income

 

84,946

 

 

76,517

 

 

11.0

%

 

247,001

 

 

224,587

 

 

10.0

%

Total revenues

 

3,731,669

 

 

3,229,404

 

 

15.6

%

 

11,483,404

 

 

9,718,382

 

 

18.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

190,355

 

 

100,932

 

 

88.6

%

 

497,700

 

 

270,355

 

 

84.1

%

Income from continuing operations

 

122,883

 

 

55,196

 

 

122.6

%

 

325,293

 

 

145,574

 

 

123.5

%

Adjusted EBITDA (a)

 

242,209

 

 

154,144

 

 

57.1

%

 

652,974

 

 

431,407

 

 

51.4

%

Net income

 

122,796

 

 

55,092

 

 

122.9

%

 

325,148

 

 

145,413

 

 

123.6

%

EPS (b)

 

0.88

 

 

0.40

 

 

120.0

%

 

2.34

 

 

1.04

 

 

125.0

%

Adjusted net income(a)

 

128,477

 

 

56,575

 

 

127.1

%

 

331,753

 

 

148,304

 

 

123.7

%

Adjusted EPS (a)

 

0.92

 

 

0.41

 

 

124.4

%

 

2.39

 

 

1.06

 

 

125.5

%

Basic weighted average shares outstanding

 

136,011

 

 

135,521

 

 

0.4

%

 

136,269

 

 

136,301

 

 

%

Diluted weighted average shares outstanding

 

139,060

 

 

138,192

 

 

0.6

%

 

139,003

 

 

139,390

 

 

(0.3)

%

  1. See “Note Regarding Non-GAAP Financial Information”
  2. EPS represents earnings per diluted share

Additional Highlights:

  • Comparable club sales for the third quarter of fiscal 2020 increased 14.1% compared to the third quarter of fiscal 2019. Comparable club sales, excluding the impact of gasoline sales, for the third quarter of fiscal 2020 increased 18.5% compared to the third quarter of fiscal 2019. Comparable club sales for the first nine months of fiscal 2020 increased 17.0% compared to the first nine months of fiscal 2019. Comparable club sales, excluding the impact of gasoline sales, for the first nine months of fiscal 2020 increased 23.2% compared to the first nine months of fiscal 2019.
  • Gross profit increased to $743.3 million in the third quarter of fiscal 2020 from $617.6 million in the third quarter of fiscal 2019. Merchandise gross margin rate, which excludes gasoline sales and membership fee income, increased by 10 basis points over the third quarter of fiscal 2019. Continued execution of our category profitability improvement was offset by distribution costs associated with the coronavirus pandemic. Gross profit increased to $2,236.4 million in the first nine months of fiscal 2020 from $1,804.6 million in the first nine months of fiscal 2019. Merchandise gross margin rate, which excludes gasoline sales and membership fee income, decreased by approximately 10 basis points over the first nine months of fiscal 2019. While merchandise margins benefited from strong sales performance and continued execution of our category profitability improvement initiatives, these drivers were offset by distribution costs associated with the coronavirus pandemic, the decline in our higher-margin apparel business and temporary shut-down of our higher-margin services business in the first quarter of fiscal 2020.
  • Selling, general and administrative expenses (“SG&A”) increased to $552.3 million in the third quarter of fiscal 2020 compared to $510.4 million in the third quarter of fiscal 2019. The year-over-year increase in SG&A expense was primarily driven by costs associated with the coronavirus pandemic, including wage increases, bonuses, safety and protective equipment and other operational costs, such as security. SG&A increased to $1,733.5 million in the first nine months of fiscal 2020 compared to $1,523.5 million in the first nine months of fiscal 2019. SG&A in the first nine months of fiscal 2019 included charges related to registered offerings by selling stockholders (“offering costs”) of $1.9 million.
  • Operating income increased to $190.4 million, or 5.1% of total revenues in the third quarter of fiscal 2020 compared to $100.9 million, or 3.1% of total revenues in the third quarter of fiscal 2019. Operating income increased to $497.7 million, or 4.3% of total revenues in the first nine months of fiscal 2020 compared to $270.4 million, or 2.8% of total revenues in the first nine months of fiscal 2019. Operating income in the first nine months of fiscal 2019 included charges related to offering costs of $1.9 million.
  • Interest expense, net, decreased to $25.9 million in the third quarter of fiscal 2020, compared to $27.7 million in the third quarter of fiscal 2019. Interest expense in the third quarter of fiscal 2020 included a $2.8 million write-off of deferred fees and the original issue discount associated with the October 2020 partial payoff of our first lien term loan facility (the “First Lien Term Loan”) and $5.1 million write-off of accumulated other comprehensive income associated with the de-designation of one of our swap agreements. Interest expense, net, decreased to $68.5 million in the first nine months of fiscal 2020, compared to $82.3 million in the first nine months of fiscal 2019. Interest expense in the first nine months of fiscal 2020 included $4.1 million of deferred fees and original issues discount associated with the partial pay offs of our First Lien Term Loan in July and October 2020. The decrease in interest expense was driven by continued de-levering. The partial debt pay down and the de-designation of one of our swap agreements will result in interest expense savings of approximately $10 million on an annualized basis.
  • Income tax expense was $41.6 million in the third quarter of fiscal 2020 compared to income tax expense of $18.0 million in the third quarter of fiscal 2019. The third quarter of fiscal 2020 included a benefit of $3.3 million from excess tax benefits related to stock-based compensation compared to $1.8 million in the third quarter of fiscal 2019. Income tax expense was $103.9 million in the first nine months of fiscal 2020 compared to income tax expense of $42.5 million in the first nine months of fiscal 2019. The first nine months of fiscal 2020 included a benefit of $10.4 million from excess tax benefits related to stock-based compensation compared to $8.4 million in the first nine months of fiscal 2019.
  • Under our share repurchase program, we repurchased 1.2 million shares of common stock, totaling $50.0 million in the third quarter of fiscal 2020. In the first nine months of fiscal 2020, we repurchased 2.3 million shares of common stock, totaling $88.1 million, under such program.

Conference Call Details

A conference call to discuss the third quarter fiscal 2020 financial results is scheduled for today, November 19, 2020, at 8:30 a.m. Eastern Time. Investors and analysts interested in participating in the call are invited to dial 877-274-0290 (international callers please dial 647-689-5405) approximately 10 minutes prior to the start of the call and reference conference ID 1057008. A live audio webcast of the conference call will be available online at https://investors.bjs.com.

A recorded replay of the conference call will be available within two hours of the conclusion of the call and can be accessed both online at https://investors.bjs.com and by dialing 416-621-4642 and entering the access code 1057008. The recorded replay will be available until November 26, 2020 and an online archive of the webcast will be available for one year.

About BJ’s Wholesale Club Holdings, Inc.

Headquartered in Westborough, Massachusetts, BJ’s Wholesale Club Holdings, Inc. is a leading operator of membership warehouse clubs in the Eastern United States. The company currently operates 219 clubs and 149 BJ’s Gas® locations in 17 states.

Non-GAAP Financial Measures

We refer to certain financial measures that are not recognized under United States generally accepted accounting principles (“GAAP”). Please see “Note Regarding Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Information” below for additional information and a reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures.

BJ’S WHOLESALE CLUB HOLDINGS, INC.

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

 

(Amounts in thousands, except per share amounts)

 

 

 

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

13 Weeks Ended

 

13 Weeks Ended

 

39 Weeks Ended

 

39 Weeks Ended

 

 

October 31, 2020

 

November 2, 2019

 

October 31, 2020

 

November 2, 2019

Net sales

 

$

3,646,723

 

 

$

3,152,887

 

 

$

11,236,403

 

 

$

9,493,795

 

Membership fee income

 

84,946

 

 

76,517

 

 

247,001

 

 

224,587

 

Total revenues

 

3,731,669

 

 

3,229,404

 

 

11,483,404

 

 

9,718,382

 

Cost of sales

 

2,988,397

 

 

2,611,758

 

 

9,247,042

 

 

7,913,820

 

Selling, general and administrative expenses

 

552,307

 

 

510,410

 

 

1,733,482

 

 

1,523,480

 

Pre-opening expense

 

610

 

 

6,304

 

 

5,180

 

 

10,727

 

Operating income

 

190,355

 

 

100,932

 

 

497,700

 

 

270,355

 

Interest expense, net

 

25,882

 

 

27,702

 

 

68,467

 

 

82,274

 

Income from continuing operations before income taxes

 

164,473

 

 

73,230

 

 

429,233

 

 

188,081

 

Provision for income taxes

 

41,590

 

 

18,034

 

 

103,940

 

 

42,507

 

Income from continuing operations

 

122,883

 

 

55,196

 

 

325,293

 

 

145,574

 

Loss from discontinued operations, net of income taxes

 

(87)

 

 

(104)

 

 

(145)

 

 

(161)

 

Net income

 

$

122,796

 

 

$

55,092

 

 

$

325,148

 

 

$

145,413

 

Income per share attributable to common stockholders – basic:

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

0.90

 

 

$

0.41

 

 

$

2.39

 

 

$

1.07

 

Loss from discontinued operations

 

 

 

 

 

 

 

 

Net income

 

$

0.90

 

 

$

0.41

 

 

$

2.39

 

 

$

1.07

 

Income per share attributable to common stockholders – diluted:

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

0.88

 

 

$

0.40

 

 

$

2.34

 

 

$

1.04

 

Loss from discontinued operations

 

 

 

 

 

 

 

 

Net income

 

$

0.88

 

 

$

0.40

 

 

$

2.34

 

 

$

1.04

 

Weighted average number of shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

136,011

 

 

135,521

 

 

136,269

 

 

136,301

 

Diluted

 

139,060

 

 

138,192

 

 

139,003

 

 

139,390

 

BJ’S WHOLESALE CLUB HOLDINGS, INC.

 

 

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

(Amounts in thousands)

 

 

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

October 31, 2020

 

November 2, 2019

ASSETS

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

46,116

 

 

$

29,968

 

 

Accounts receivable, net

 

188,413

 

 

185,983

 

 

Merchandise inventories

 

1,264,323

 

 

1,271,172

 

 

Prepaid expense and other current assets

 

97,116

 

 

55,285

 

 

 

Total current assets

 

1,595,968

 

 

1,542,408

 

 

 

 

 

 

 

 

Operating lease right-of-use assets, net

 

2,034,742

 

 

2,067,626

 

Property and equipment, net

 

769,258

 

 

775,659

 

Goodwill

 

924,134

 

 

924,134

 

Intangibles, net

 

138,088

 

 

150,357

 

Other assets

 

20,094

 

 

17,897

 

 

 

Total assets

 

$

5,482,284

 

 

$

5,478,081

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

Current liabilities:

 

 

 

 

 

Current portion of long-term debt

 

$

260,000

 

 

$

449,377

 

 

Current portion of operating lease liabilities

 

131,025

 

 

121,961

 

 

Accounts payable

 

1,176,104

 

 

973,328

 

 

Accrued expenses and other current liabilities

 

643,309

 

 

507,141

 

 

 

Total current liabilities

 

2,210,438

 

 

2,051,807

 

 

 

 

 

 

 

 

Long-term lease liabilities

 

1,961,321

 

 

1,980,447

 

Long-term debt

 

845,696

 

 

1,339,700

 

Deferred income taxes

 

47,241

 

 

50,486

 

Other noncurrent liabilities

 

200,210

 

 

160,127

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY (DEFICIT)

 

217,378

 

 

(104,486)

 

 

 

Total liabilities and stockholders’ equity (deficit)

 

$

5,482,284

 

 

$

5,478,081

 

BJ’S WHOLESALE CLUB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)

 

 

39 Weeks Ended

October 31,

2020

 

39 Weeks Ended

November 2,

2019

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

Net income

 

$

325,148

 

 

$

145,413

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

124,331

 

 

116,920

 

Amortization of debt issuance costs and accretion of original issue discount

 

3,470

 

 

3,969

 

Debt extinguishment charges

 

4,077

 

 

2,032

 

Stock-based compensation expense

 

23,245

 

 

13,984

 

Deferred income tax provision

 

2,289

 

 

14,846

 

Other non cash items, net

 

5,441

 

 

2,539

 

Increase (decrease) in cash due to changes in:

 

 

 

 

Accounts receivable

 

17,940

 

 

8,317

 

Merchandise inventories

 

(182,821)

 

 

(218,866)

 

Accounts payable

 

389,692

 

 

156,448

 

Accrued expenses

 

61,829

 

 

(35,004)

 

Other operating assets and liabilities, net

 

27,331

 

 

10,924

 

Net cash provided by operating activities

 

801,972

 

 

221,522

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

Additions to property and equipment, net of disposals

 

(152,800)

 

 

(144,428)

 

Proceeds from sale leaseback transaction

 

25,893

 

 

 

Net cash used in investing activities

 

(126,907)

 

 

(144,428)

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

Payments on long term debt

 

(3,297)

 

 

(11,533)

 

Paydown of First Lien Term Loan

 

(510,000)

 

 

(200,000)

 

Net (payment) borrowings on ABL Facility

 

(68,000)

 

 

195,000

 

Net cash received from stock option exercises

 

16,431

 

 

9,293

 

Net cash received from Employee Stock Purchase Program (ESPP)

 

1,107

 

 

726

 

Acquisition of treasury stock

 

(94,671)

 

 

(67,305)

 

Other financing activities

 

(723)

 

 

(453)

 

Net cash used in financing activities

 

(659,153)

 

 

(74,272)

 

Net increase in cash and cash equivalents

 

15,912

 

 

2,822

 

Cash and cash equivalents at beginning of period

 

30,204

 

 

27,146

 

Cash and cash equivalents at end of period

 

$

46,116

 

 

$

29,968

 

Note Regarding Non-GAAP Financial Information

This press release includes financial measures that are not calculated in accordance with GAAP, including adjusted net income, adjusted net income per diluted share, adjusted EBITDA, free cash flow and net debt and net debt to LTM adjusted EBITDA.

We define adjusted net income as net income attributable to common stockholders adjusted for: stock-based compensation related to the IPO; offering costs; management fees; club closing and impairment charges; reduction in force severance; gain on sale leaseback transactions; charges related to debt restructurings and retirements; and the tax impact of the foregoing adjustments on net income.

We define adjusted net income per diluted share as adjusted net income divided by the weighted average diluted shares outstanding.

We define adjusted EBITDA as income from continuing operations before interest expense, net, provision for income taxes and depreciation and amortization, adjusted for the impact of certain other items, including: stock-based compensation expense; pre-opening expenses; non-cash rent; strategic consulting; offering costs; and other adjustments.

We define free cash flow as net cash provided by operating activities less additions to property and equipment, net of disposals plus proceeds from sale leaseback transaction.

We define net debt as total debt outstanding less cash and cash equivalents.

We define net debt to LTM adjusted EBITDA as net debt at the balance sheet date divided by adjusted EBITDA for the trailing twelve-month period.

We present adjusted net income, adjusted net income per diluted share and adjusted EBITDA, which are not recognized financial measures under GAAP, because we believe such measures assists investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, adjusted EBITDA excludes pre-opening expenses, because we do not believe these expenses are indicative of the underlying operating performance of our stores. The amount and timing of pre-opening expenses are dependent on, among other things, the size of new stores opened and the number of new stores opened during any given period.

Management believes that adjusted net income, adjusted net income per diluted share and adjusted EBITDA are helpful in highlighting trends in our core operating performance compared to other measures, which can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which companies operate and capital investments. We use adjusted net income, adjusted net income per diluted share and adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies; to make budgeting decisions; and to compare our performance against that of other peer companies using similar measures. We also use adjusted EBITDA in connection with establishing discretionary annual incentive compensation.

We present free cash flow, which is not a recognized financial measure under GAAP, because we use it to report to our board of directors and we believe it assists investors and analysts in evaluating our liquidity. Free cash flow should not be considered as an alternative to cash flows from operations as a liquidity measure. We present net debt and net debt to LTM adjusted EBITDA, which are not recognized as financial measures under GAAP, because we use them to report to our board of directors and we believe they assist investors and analysts in evaluating our borrowing capacity. Net debt to LTM adjusted EBITDA is a key financial measure that is used by management to assess the borrowing capacity of the Company.

You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating adjusted net income, adjusted net income per diluted share, adjusted EBITDA and net debt to LTM adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or like some of the adjustments in our presentation of these metrics. Our presentation of adjusted net income, adjusted net income per diluted share, adjusted EBITDA, free cash flow, net debt and net debt to LTM adjusted EBITDA should not be considered as alternatives to any other measure derived in accordance with GAAP and they should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. There can be no assurance that we will not modify the presentation of adjusted net income, adjusted net income per diluted share, adjusted EBITDA or net debt to LTM adjusted EBITDA in the future, and any such modification may be material. In addition, adjusted net income, adjusted net income per diluted share, adjusted EBITDA, free cash flow, net debt and net debt to LTM adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries. Additionally, adjusted net income, adjusted net income per diluted share, adjusted EBITDA, free cash flow, net debt and net debt to LTM adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP.

Reconciliation of GAAP to Non-GAAP Financial Information

BJ’S WHOLESALE CLUB HOLDINGS, INC.

 

 

 

 

 

 

Reconciliation of net income to adjusted net income and adjusted net income per diluted share

(Amounts in thousands, except per share amounts)

(Unaudited)

 

13 Weeks Ended

 

13 Weeks Ended

 

39 Weeks Ended

 

39 Weeks Ended

 

October 31, 2020

 

November 2, 2019

 

October 31, 2020

 

November 2, 2019

Net income as reported

$

122,796

 

 

$

55,092

 

 

$

325,148

 

 

$

145,413

 

Adjustments:

 

 

 

 

 

 

 

Offering costs (a)

 

 

 

 

 

 

1,928

 

Charges and write-offs related to debt paydown (b)

2,794

 

 

2,032

 

 

4,077

 

 

2,032

 

Loss on cash flow hedge (c)

5,097

 

 

 

 

5,097

 

 

 

Tax impact of adjustments to net income (d)

(2,210)

 

 

(549)

 

 

(2,569)

 

 

(1,069)

 

Adjusted net income

$

128,477

 

 

$

56,575

 

 

$

331,753

 

 

$

148,304

 

 

 

 

 

 

 

 

 

Weighted average diluted shares outstanding

139,060

 

 

138,192

 

 

139,003

 

 

139,390

 

Adjusted net income per diluted share (e)

$

0.92

 

 

$

0.41

 

 

$

2.39

 

 

$

1.06

 

  1. Represents costs related to registered offerings by selling stockholders.
  2. Represents the write-off of deferred fees and original issue discount associated with the partial paydown of our First Lien Term Loan.
  3. Represents the reclassification into earnings of accumulated other comprehensive income associated with the de-designation of hedge accounting on one of our swap agreements due to the paydown of the First Lien Term Loan.
  4. Represents the tax effect of the above adjustments at a statutory tax rate of approximately 28%.
  5. Adjusted net income per diluted share is measured using weighted average diluted shares outstanding.

BJ’S WHOLESALE CLUB HOLDINGS, INC.

 

 

 

 

 

Reconciliation to Adjusted EBITDA

(Amounts in thousands)

(Unaudited)

 

 

13 Weeks Ended

 

13 Weeks Ended

 

39 Weeks Ended

 

39 Weeks Ended

 

 

October 31, 2020

 

November 2, 2019

 

October 31, 2020

 

November 2, 2019

Income from continuing operations

 

$

122,883

 

 

$

55,196

 

 

$

325,293

 

 

$

145,574

 

Interest expense, net

 

25,882

 

 

27,702

 

 

68,467

 

 

82,274

 

Provision for income taxes

 

41,590

 

 

18,034

 

 

103,940

 

 

42,507

 

Depreciation and amortization

 

42,160

 

 

39,249

 

 

124,331

 

 

116,920

 

Stock-based compensation expense (a)

 

8,667

 

 

5,188

 

 

23,245

 

 

13,984

 

Pre-opening expenses (b)

 

610

 

 

6,304

 

 

5,180

 

 

10,727

 

Non-cash rent (c)

 

274

 

 

2,558

 

 

2,289

 

 

6,331

 

Strategic consulting (d)

 

 

 

 

 

 

 

11,349

 

Offering costs (e)

 

 

 

 

 

 

 

1,928

 

Other adjustments (f)

 

143

 

 

(87)

 

 

229

 

 

(187)

 

Adjusted EBITDA

 

$

242,209

 

 

$

154,144

 

 

$

652,974

 

 

$

431,407

 

  1. Represents total stock-based compensation expense.
  2. Represents direct incremental costs of opening or relocating a facility that are charged to operations as incurred.
  3. Consists of an adjustment to remove the non-cash portion of rent expense.
  4. Represents fees paid to external consultants for strategic initiatives of limited duration.
  5. Represents costs related to registered offerings by selling stockholders.
  6. Other non-cash items, including non-cash accretion on asset retirement obligations and obligations associated with our post-retirement medical plan.

BJ’S WHOLESALE CLUB HOLDINGS, INC.

 

 

 

 

 

Reconciliation to Free Cash Flow

 

 

 

 

 

(Amounts in thousands)

 

 

 

 

 

 

 

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

13 Weeks Ended

 

13 Weeks Ended

 

39 Weeks Ended

 

39 Weeks Ended

 

 

October 31, 2020

 

November 2, 2019

 

October 31, 2020

 

November 2, 2019

Net cash provided by operating activities

 

$

68,280

 

 

$

6,398

 

 

$

801,972

 

 

$

221,522

 

Less: Additions to property and equipment, net of disposals

 

69,838

 

 

56,130

 

 

152,800

 

 

144,428

 

Plus: Proceeds from sale leaseback transaction

 

21,832

 

 

 

 

25,893

 

 

 

Free cash flow

 

$

20,274

 

 

$

(49,732)

 

 

$

675,065

 

 

$

77,094

 

BJ’S WHOLESALE CLUB HOLDINGS, INC.

 

 

Reconciliation of Net Debt and Net Debt to LTM adjusted EBITDA

 

 

(Amounts in thousands)

 

 

(Unaudited)

 

 

 

 

October 31, 2020

Total debt

 

$

1,105,696

 

Less: Cash and cash equivalents

 

46,116

 

Net Debt

 

$

1,059,580

 

 

 

 

Income from continuing operations

 

367,476

 

Interest expense, net

 

94,423

 

Provision for income taxes

 

117,645

 

Depreciation and amortization

 

164,411

 

Stock-based compensation expense (a)

 

28,057

 

Pre-opening expenses (b)

 

9,605

 

Non-cash rent (c)

 

4,332

 

Reduction in force severance (d)

 

3,994

 

Club closings and impairment charges (e)

 

15,383

 

Other adjustments (f)

 

(2,135)

 

Adjusted EBITDA

 

$

803,191

 

 

 

 

Net debt to LTM adjusted EBITDA

 

1.3x

  1. Represents total stock-based compensation expense.
  2. Represents direct incremental costs of opening or relocating a facility that are charged to operations as incurred.
  3. Consists of an adjustment to remove the non-cash portion of rent expense.
  4. Represents severance charges associated with a reduction in workforce announced in January 2020.
  5. Represents primarily closing costs associated with our clubs in Charlotte, N.C. and Geneva, N.Y., which closed in the fourth quarter of fiscal 2019 and other impairment charges.
  6. Other non-cash items, including a gain from the sale leaseback of one of our new Michigan locations, non-cash accretion on asset retirement obligations, termination costs to former executives and obligations associated with our post-retirement medical plan.

 

Investors:

Faten Freiha, BJ’s Wholesale Club

(774) 512-6320

[email protected]

Media:

Jennie Hardin, BJ’s Wholesale Club

(774) 512-6978

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Food/Beverage Home Goods Retail Department Stores Supermarket

MEDIA:

Logo
Logo

Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan

  • 52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS

WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) —  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the first patient has been dosed in the potentially registrational Phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS).

Studies suggest that elevated levels of C3 may play a role in the progression of ALS, a neurodegenerative disease that leads to progressive muscle weakness and paralysis. The MERIDIAN study will assess whether pegcetacoplan may offer a new treatment approach for people living with ALS by controlling complement activation at the level of C3. There are currently no treatments to slow the advance of ALS.

“ALS patients have a very high unmet need. They expect more and better treatment options,” said Bashar Al-Nakhala, chief operations officer of the ALS Therapeutic Development Institute. “We are pleased that Apellis and Sobi have joined the ALS clinical development community with our shared goal of halting the devastating progression of ALS.”

“Based on the suspected role of C3 in ALS, we are working urgently to understand whether pegcetacoplan, a targeted C3 therapy, has the potential to slow disease progression and make a difference for the ALS community,” said Federico Grossi, M.D., Ph.D, chief medical officer of Apellis. “We designed the MERIDIAN study based on significant feedback from the community, and we are dedicated to continuing our partnership to one day bring a meaningful therapy to families living with ALS.”

“We are delighted that the first patient in the Phase 2 clinical study has been dosed as there is an urgency for a treatment for patients with ALS,” said Ravi Rao, head of R&D and chief medical officer at Sobi. “In collaboration with Apellis, we look forward to evaluating the potential of pegcetacoplan in patients with ALS.”

The Phase 2 MERIDIAN study (APL2-ALS-206) is a potentially registrational, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of pegcetacoplan in approximately 200 adults with sporadic ALS. Study participants will be randomized in a 2:1 ratio to receive pegcetacoplan or placebo while continuing to receive their existing standard of care treatment for ALS. After 52 weeks of blinded treatment, all patients in the study will receive pegcetacoplan. To reduce the burden on people living with ALS and their caregivers, the study has been designed to minimize the number of in-clinic visits, with approximately six clinic visits in the first year and four in the open-label second year.

The primary endpoint of the study is the Combined Assessment of Function and Survival (CAFS) rank scores at week 52. Key secondary endpoints include measures of lung function, muscle strength, and quality of life. For more information about the Phase 2 MERIDIAN study, visit https://www.clinicaltrials.gov (NCT04579666).

About
Amyotrophic Lateral Sclerosis
(ALS)

ALS is a devastating neurodegenerative disease that results in progressive muscle weakness and paralysis due to the death of nerve cells, called motor neurons, in the brain and spinal cord.1,2 The death of motor neurons leads to the progressive loss of voluntary muscle movement required for speaking, walking, swallowing, and breathing.1,2 In individuals with ALS, high levels of C3 are present at the neuromuscular junction3 where motor neurons communicate directly to muscle cells. Numerous studies suggest that elevated levels of C3 present throughout the motor system of ALS patients are likely to contribute to chronic neuroinflammation and the death of motor neurons.3,4,5 There are currently no approved treatments that stop or reverse the progression of ALS, which impacts ~225,000 patients worldwide.6

About
Pegcetacoplan
(APL-2)

Pegcetacoplan is an investigational, targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. Marketing applications for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) are under review by the U.S. Food and Drug Administration (FDA), which has granted the application Priority Review designation, and the European Medicines Agency (EMA). Pegcetacoplan was also granted Fast Track designation by the FDA for the treatment of PNH and for the treatment of geographic atrophy and received orphan drug designation for the treatment of C3 glomerulopathy by the FDA and EMA. For additional information regarding pegcetacoplan clinical trials, visit https://apellis.com/our-science/clinical-trials.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of hematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi’s revenues amounted to SEK 14.2 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

Apellis Forward-Looking Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the company’s clinical trials will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether pegcetacoplan will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company’s clinical trials will warrant regulatory submissions and whether pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for GA, PNH, CAD, C3G, IC-MPGN, ALS or any other indication when expected or at all; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2020 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information please contact

Apellis

Media
Tracy Vineis
[email protected]
+1 617 420 4839

Investor Contact:

Argot Partners
[email protected]
+1 212.600.1902

Sobi

Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
[email protected] 

Linda Holmström, Corporate Communication & Investor Relations
+ 46 708 734 095
[email protected]

1 National Institute of Neurological Disorders and Stroke. (2020). Amyotrophic Lateral Sclerosis Fact Sheet. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-lateral-Sclerosis-ALS-Fact-Sheet
2 ALS Association. What is ALS? Retrieved June 2020 from https://www.als.org/understanding-als/what-is-als
3 Bahia El Idrissi N, et al. J Neuroinflammation. 2016;13(1):72.4 Sta M, et al. Neurobiol Dis. 2011;42(3):211-220.
4 Woodruff, et al., PNAS January 7, 2014 111 (1) E3-E4
5 Lee, et al Journal of Neuroinflammation volume 15: 171 (2018)25 Arthur K et al. Nat Commun, 2016, Vol 7, article 12408
6 Arthur K et al. Nat Commun, 2016, Vol 7, article 12408

 



Lands’ End Announces Third Quarter Fiscal 2020 Earnings Conference Call

DODGEVILLE, Wis., Nov. 19, 2020 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) will host a conference call at 8:30 a.m. Eastern Time on Thursday, December 3, 2020, to discuss its third quarter fiscal 2020 financial results. A news release containing these results will be issued before the call. Listeners may access a live broadcast of the conference call on the Company’s investor relations website: http://investors.landsend.com/ in the Events and Presentations section or by dialing (866) 753-5836.

An online archive of the broadcast will be available at approximately noon on December 3, 2020, and will be accessible on the Company’s website: http://investors.landsend.com/ in the Events and Presentations section.

About Lands’ End, Inc.

Lands’ End, Inc. (NASDAQ:LE) is a leading uni-channel retailer of casual clothing, accessories, footwear and home products. We offer products online at www.landsend.com, on third party online marketplaces and through retail locations. We are a classic American lifestyle brand with a passion for quality, legendary service and real value, and seek to deliver timeless style for women, men, kids and the home.

CONTACT:

Lands’ End, Inc.
James Gooch
Chief Operating Officer and Chief Financial Officer
(608) 935-9341

Investor Relations:
ICR, Inc.
Jean Fontana
(646) 277-1214

[email protected]



Ovintiv Names Meg A. Gentle to Board of Directors

PR Newswire

DENVER, Nov. 19, 2020 /PRNewswire/ – Ovintiv Inc. (NYSE: OVV) (TSX: OVV) today announced that Meg A. Gentle has been named as an independent member of its board of directors, effective December 16, 2020.

Gentle, 46, currently serves as the president and chief executive officer of Tellurian, Inc. and as a member of its board of directors. Before joining Tellurian in 2016, she served as CFO and executive vice president of marketing for Cheniere Energy. Gentle graduated from James Madison University and holds an MBA from Rice University.

Fred J. Fowler, 75, Ovintiv director since 2010, will not seek re-election at the Company’s 2021 annual meeting and will retire from the board at that time.

“I’m very pleased that Meg is joining our board. Her skills and experiences will complement the strengths of our other board members,” said Ovintiv Chairman Peter Dea. “We are thankful for Fred’s wisdom and commitment to our Company over the past 10 years.”

Since early 2019, including Gentle, the Company has added three new directors, appointed a new independent board chairman and refreshed its committee memberships, including three new committee chairs.

About Ovintiv Inc.
Ovintiv is one of the largest producers of oil, condensate and natural gas in North America. The Company is committed to preserving its financial strength, maximizing profitability through disciplined capital investments and operational efficiencies and returning capital to shareholders. A talented team, in combination with a culture of innovation and efficiency, fuels Ovintiv’s economic performance, increases shareholder value and strengthens its commitment to sustainability in the communities where its employees live and work.

Further information on Ovintiv Inc. is available on the Company’s website, www.ovintiv.com, or by contacting:



Investor contact:


(888) 525-0304 



Media contact:


(281) 210-5253

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ovintiv-names-meg-a-gentle-to-board-of-directors-301176785.html

SOURCE Ovintiv Inc.

Höegh LNG Partners LP Reports Financial Results for the Quarter Ended September 30, 2020

PR Newswire

HAMILTON, Bermuda, Nov. 19, 2020 /PRNewswire/ — Höegh LNG Partners LP (NYSE: HMLP) (the “Partnership”) today reported its financial results for the quarter ended September 30, 2020.

Highlights

  • Continued measures to mitigate the risks from the COVID-19 pandemic and ensure health and safety of crews and staff, whose wellbeing is the Partnership’s highest priority
  • 100% availability of FSRUs for the third quarter of 2020
  • Reported total time charter revenues of $35.9 million for the third quarter of 2020 compared to $37.0 million of time charter revenues for the third quarter of 2019
  • Generated operating income of $28.1 million, net income of $19.5 million and limited partners’ interest in net income of $15.8 million for the third quarter of 2020 compared to operating income of $23.4 million, net income of $13.7 million and limited partners’ interest in net income of $10.2 million for the third quarter of 2019
  • Operating income, net income and limited partners’ interest in net income were impacted by unrealized gains on derivative instruments for the third quarter of 2020 compared with unrealized losses on derivative instruments for the third quarter of 2019 mainly on the Partnership’s share of equity in earnings of joint ventures
  • Excluding the impact of the unrealized gains (losses) on derivative instruments for the third quarter of 2020 and 2019 impacting the equity in earnings of joint ventures, operating income for the three months ended September 30, 2020 would have been $25.8 million, an increase of $0.2 million from $25.6 million for the three months ended September 30, 2019
  • Generated Segment EBITDA1 of $36.4 million for each of the third quarter of 2020 and 2019
  • On November 13, 2020, paid a $0.44 per unit distribution on common units with respect to the third quarter of 2020, equivalent to $1.76 per unit on an annualized basis
  • On November 16, 2020, paid a distribution of $0.546875 per 8.75% Series A cumulative redeemable preferred unit (“Series A preferred unit”), for the period commencing on August 15, 2020 to November 14, 2020

Sveinung J.S. Støhle, Chief Executive Officer stated: “In the third quarter, we are very pleased to have once again delivered a high level of safe and reliable operating and financial performance, despite the continuing challenges presented by COVID-19. The Partnership’s ability to achieve a full quarter of 100% availability for our fleet of high-quality, modern FSRUs enabled us to maximize the value of our long-term, fixed-rate contracts and to demonstrate the robust distribution coverage inherent in our more than 8.5 years of average remaining contract cover. Liquid natural gas is readily available and highly cost competitive globally, and it is clear that LNG will play a leading role in driving the energy transition for decades to come.”

1 Segment EBITDA is a non-GAAP financial measure used by investors to measure financial and operating performance. Please see Appendix A for a reconciliation of Segment EBITDA to net income, the most directly comparable GAAP financial measure.

Financial Results Overview

For the three months ended September 30, 2020, each of the Partnership’s FSRUs have had 100% availability due to the diligent efforts of the crew and staff to ensure all aspects of operations continued to function smoothly in spite of challenges as a result of the COVID-19 pandemic. The Partnership has mitigated the risk of an outbreak of the Coronavirus on board its vessels by extending time between crew rotations on the vessels and developing mitigating actions for crew rotations. Management and administrative staffs have largely transitioned to working remotely from home to address the specific COVID-19 situation in the applicable geographic location. The Partnership has fulfilled its obligations under the time charter contracts and not experienced any off-hire for its FSRUs for the three months ended September 30, 2020.

The Partnership reported net income of $19.5 million for the three months ended September 30, 2020, an increase of $5.8 million from net income of $13.7 million for the three months ended September 30, 2019. Net income was impacted by unrealized gains on derivative instruments for the third quarter of 2020 compared with unrealized losses for the third quarter of 2019, mainly included in the Partnership’s share of equity in earnings of joint ventures.

Excluding the impact of all of the unrealized gains (losses) on derivative instruments, net income for the three months ended September 30, 2020 would have been $17.3 million, an increase of $1.4 million from $15.9 million for the three months ended September 30, 2019. Excluding the impact of the unrealized gains (losses) on derivatives, the increase for the three months ended September 30, 2020, is primarily due to lower total operating expenses, improved results for the equity in earnings of joint ventures and lower interest expense which were partially offset by the impact of lower time charter revenues.

Preferred unitholders’ interest in net income was $3.7 million for the three months ended September 30, 2020, an increase of $0.2 million from $3.5 million for the three months ended September 30, 2019, which was due to additional preferred units issued as part of the at-the-market offering program (“ATM program”). Limited partners’ interest in net income for the three months ended September 30, 2020 was $15.8 million, an increase of $5.6 million from limited partners’ interest in net income of $10.2 million for the three months ended September 30, 2019. Excluding all of the unrealized gains and losses on derivative instruments, limited partners’ interest in net income for the three months ended September 30, 2020 would have been $13.6 million, an increase of $1.1 million from $12.5 million for the three months ended September 30, 2019. 

The PGN FSRU Lampung, the Höegh Gallant and the Höegh Grace were on-hire for the entire third quarter of 2020 and 2019.

Equity in earnings of joint ventures was $5.8 million for the three months ended September 30, 2020, an increase of $5.2 million from $0.6 million for the three months ended September 30, 2019. The joint ventures own the Neptune and the Cape Ann. Unrealized gains and losses on derivative instruments in the joint ventures significantly impacted the equity in earnings of joint ventures for the three months ended September 30, 2020 and 2019. The joint ventures do not apply hedge accounting for interest rate swaps and all changes in fair value are included in equity in earnings (losses) of joint ventures. Excluding the unrealized gains and losses for the three months ended September 30, 2020 and 2019, the equity in earnings of joint ventures would have been $3.6 million for the three months ended September 30, 2020, an increase of $0.8 million compared to equity in earnings of joint ventures of $2.8 million for the three months ended September 30, 2019. Excluding the unrealized gains (losses) on derivative instruments, the increase was mainly due to lower vessel operating expenses incurred for maintenance and lower administrative and interest expenses between the periods. For the three months ended September 30, 2019, the Neptune completed an on-water class renewal survey and routine maintenance was completed during the survey. The Neptune was on-hire during the class renewal period.

Operating income for the three months ended September 30, 2020 was $28.1 million, an increase of $4.7 million from $23.4 million for the three months ended September 30, 2019. Excluding the impact of the unrealized gains (losses) on derivatives for the three months ended September 30, 2020 and 2019 impacting the equity in earnings of joint ventures, operating income for the three months ended September 30, 2020 would have been $25.8 million, an increase of $0.2 million from $25.6 million for the three months ended September 30, 2019.

Segment EBITDA1 was $36.4 million for each of the three months ended September 30, 2020 and 2019.

Effective January 1, 2020, the Partnership adopted the new accounting standard, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, with recognition of a net decrease to retained earnings of $0.16 million as of January 1, 2020 for the cumulative effect of adopting the new standard. The cumulative effect includes allowances for expected credit losses related to the net investment in financing lease and trade receivables. For the three months ended September 30, 2020, there was no change in the allowance for expected credit losses. 

Financing and Liquidity

As of September 30, 2020, the Partnership had cash and cash equivalents of $25.0 million. Current restricted cash for operating obligations of the PGN FSRU Lampung was $6.5 million and long-term restricted cash required under the Lampung facility was $12.2 million as of September 30, 2020. As of November 19, 2020, the Partnership had an undrawn balance of $14.7 million on the $63 million revolving credit tranche of the $385 million facility and an undrawn balance of $63.0 million on the $85 million revolving credit facility from Höegh LNG.

As of September 30, 2020, the Partnership has no material commitments for capital expenditures. However, during the fourth quarter of 2020, part of the procedures for the on-water class renewal survey for the Höegh Grace will be performed. No off-hire is expected during the fourth quarter of 2020. The remainder of the on-water class renewal survey is expected to be completed during the first half of 2021. Expenditures of approximately $0.6 million are expected to be incurred by December 31, 2020 in connection with the survey. In addition, the joint ventures have a remaining outstanding liability for a boil-off claim under the time charters totaling $6.5 million as of September 30, 2020. The Partnership’s 50% share of the liability is $3.3 million as of September 30, 2020. In February 2020, each of the joint ventures and the charterer reached a commercial settlement addressing all the past and future claims. The final settlement and release agreements were signed on and had an effective date of April 1, 2020. Among other things, the settlement provides that 1) the boil-off claim, up to the signature date of the settlement agreements, will be settled for an aggregate amount of $23.7 million, paid in instalments during 2020, 2) the costs of the arbitration tribunal will be equally split between the two parties and each party will settle its legal and other costs, 3) the joint ventures have or will implement technical upgrades on the vessels at their own cost to minimize boil-off, and 4) the relevant provisions of the time charters were amended regarding the computation and settlement of prospective boil-off claims. The first instalment of the settlement of $17.2 million was paid by the joint ventures in April 2020. The Partnership’s 50% share was $8.6 million. The joint ventures expect to pay the remaining instalment, which is due no later than December 15, 2020, with accumulated cash balances on the joint ventures’ respective balance sheets as of September 30, 2020 and with cash from operations in 2020.

The Partnership is indemnified by Höegh LNG for its share of the cash impact of the settlement, the arbitration costs and any legal expenses, the technical modifications of the vessels and any prospective boil-off claims or other direct impacts of the settlement agreement. On April 8, 2020, the Partnership was indemnified by Höegh LNG for its share of the joint ventures boil-off settlement payments by a reduction of $8.6 million on its outstanding balance on the $85 million revolving credit facility from Höegh LNG. The remaining amount of the indemnification for the boil-off claim will be settled when the amount is paid to the charterer.

During the third quarter of 2020, the Partnership made quarterly repayments of $4.8 million on the Lampung facility and $6.4 million on the $385 million facility. In addition, the Partnership drew $6.6 million on the $85 million revolving credit facility from Höegh LNG on August 7, 2020. The Partnership’s book value and outstanding principal of total long-term debt was $436.5 million and $443.9 million, respectively, as of September 30, 2020, including the Lampung and the $385 million facilities (including the associated $63 million revolving credit facility) and the $85 million revolving credit facility.

As of September 30, 2020, the Partnership’s total current liabilities exceeded total current assets by $15.7 million. This is partly a result of the current portion of long-term debt of $44.7 million being classified as current while restricted cash of $12.2 million associated with the Lampung facility is classified as long-term. The current portion of long-term debt reflects principal payments for the next twelve months which will be funded, for the most part, by future cash flows from operations. The Partnership does not intend to maintain a cash balance to fund the next twelve months’ net liabilities. 

The Partnership believes its current resources, including the undrawn balances under the $85 million revolving credit facility and the $63 million revolving credit tranche of the $385 million facility, will be sufficient to meet the Partnership’s working capital requirements for its business for the next twelve months.

As of September 30, 2020, the Partnership had outstanding interest rate swap agreements for a total notional amount of $334.5 million to hedge against the interest rate risks of its long-term debt under the Lampung and the $385 million facilities. The Partnership applies hedge accounting for derivative instruments related to those facilities. The Partnership receives interest based on three month US dollar LIBOR and pays a fixed rate of 2.8% for the Lampung facility. The Partnership receives interest based on the three month US dollar LIBOR and pays a fixed rate of an average of approximately 2.8% for the $385 million facility. The carrying value of the liability for derivative instruments was a net liability of $28.9 million as of September 30, 2020.

The Partnership’s share of the joint ventures is accounted for using the equity method. As a result, the Partnership’s share of the joint ventures’ cash, restricted cash, outstanding debt, interest rate swaps and other balance sheet items are reflected net on the line “accumulated earnings in joint ventures” on the consolidated balance sheet and are not included in the balance sheet figures disclosed above.

On August 7, 2020, the Partnership drew $6.6 million on the $85 million revolving credit facility from Höegh LNG.

On August 14, 2020, the Partnership paid a cash distribution of $15.0 million, or $0.44 per common unit, with respect to the second quarter of 2020, equivalent to $1.76 per unit on an annualized basis.

On August 17, 2020, the Partnership paid a cash distribution of $3.7 million, or $0.546875 per Series A preferred unit, for the period commencing on May 15, 2020 to August 14, 2020.

For the period from July 1, 2020 to September 30, 2020, the Partnership sold 11,383 Series A preferred units under the ATM program at an average gross sales price of $24.02 per unit and received net proceeds, after sales commissions, of $0.3 million. The Partnership did not issue any common units under the ATM program during the three and nine months ended September 30, 2020.

On October 23, 2020, the Partnership drew $10.65 million on the $85 million revolving credit facility from Höegh LNG.

On November 13, 2020, the Partnership paid a distribution of $15.1 million, or $0.44 per common unit, with respect to the third quarter of 2020, equivalent to $1.76 per unit on an annualized basis.

On November 16, 2020, the Partnership paid a distribution of $3.7 million, or $0.546875 per Series A preferred unit for the period commencing on August 15, 2020 to November 14, 2020.

For the period from October 1, 2020 to November 17, 2020, the Partnership sold an aggregate of 32,951 Series A preferred units under the ATM program at an average gross sales price of $24.12 per unit and received net proceeds, after sales commissions, of $0.8 million.

Outlook

Höegh LNG has indemnified the Partnership for the joint ventures’ boil-off settlement, leased the Höegh Gallant under lease and maintenance agreement with a subsidiary of Höegh LNG (“Subsequent Charter”) and provided the Partnership the $85 million revolving credit facility. Höegh LNG’s ability to make payments to the Partnership under the indemnification for the boil-off settlement, the Subsequent Charter, and funding requests under the $85 million revolving credit facility may be affected by events beyond the control of Höegh LNG or the Partnership, including opportunities to obtain new employment for the Höegh Gallant and prevailing economic, financial and industry conditions. If market or other economic conditions deteriorate, Höegh LNG’s ability to meet its obligations to the Partnership may be impaired. If Höegh LNG is unable to meet its obligations to the Partnership under the indemnification for the boil-off settlement, the Subsequent Charter or meet funding requests, the Partnership’s financial condition, results of operations and ability to make cash distributions to unitholders could be materially adversely affected.

The recent outbreak of Coronavirus (COVID-19) has negatively affected economic conditions in many parts of the world which may impact the Partnership’s operations and the operations of its customers and suppliers. Although the Partnership’s operations have not been materially affected by the Coronavirus outbreak to date, the ultimate length and severity of the Coronavirus outbreak and its potential impact on the Partnership’s operations and financial condition is uncertain at this time. The Partnership believes its primary risk and exposure related to uncertainty of cash flows from its long-term time charter contracts is due to the credit risk associated with the individual charterers. Payments are due under time charter contracts regardless of the demand for the charterer’s gas output or the utilization of the FSRU. It is therefore possible that charterers may not make payments for time charter services in times of reduced demand. As of November 19, 2020, the Partnership has not experienced any reduced or non-payments for obligations under the Partnership’s time charter contracts. In addition, the Partnership has not provided concessions or made changes to the terms of payment for its customers. Furthermore, should there be an outbreak of the Coronavirus on board one of the Partnership’s FSRUs or an inability to replace critical supplies or replacement parts due to disruptions to third-party suppliers, adequate crewing or supplies may not be available to fulfill the Partnership’s obligations under its time charter contracts. This could result in off-hire or warranty payments under performance guarantees which would reduce revenues for the impacted period. To date, the Partnership has mitigated the risk of an outbreak of the Coronavirus on board its vessels by extending time between crew rotations on the vessels and developing mitigating actions for crew rotations. As a result, the Partnership expects that it may incur somewhat higher crewing expenses to ensure appropriate mitigation actions are in place to minimize risks of outbreaks. To date, the Partnership has not had service interruptions on the Partnership’s vessels. Management and administrative staffs have largely transitioned to working remotely from home to address the specific COVID-19 situation in the applicable geographic location. The Partnership has supported staffs by supplying needed internet boosters and office equipment to facilitate an effective work environment. In addition, if financial institutions providing the Partnership’s interest rate swaps or lenders under the revolving credit facility are unable to meet their obligations, the Partnership could experience a higher interest expense or be unable to obtain funding. Since implementing its prior ATM program in January 2018 until November 19, 2020, the Partnership has sold preferred units and common units for total net proceeds of $60.5 million which has supplemented the Partnership’s liquidity. In current market conditions with lower unit prices, sales under the new ATM program is a less viable and more expensive option for accessing liquidity. If the Partnership’s charterers or lenders are unable to meet their obligations under their respective contracts or if the Partnership is unable to fulfill its obligations under time charters, its financial condition, results of operations and ability to make cash distributions to unitholders could be materially adversely affected. The Partnership has long term debt maturing in October 2021 when the Lampung facility must be refinanced. The Partnership is exploring options to refinance the Lampung facility and expects to be successful in the refinancing. Should the Partnership be unable to obtain refinancing for the Lampung facility in 2021, it may not have sufficient funds or other assets to satisfy all its obligations, which would have a material adverse effect on its business, results of operations and financial condition.

Pursuant to the omnibus agreement that the Partnership entered into with Höegh LNG at the time of the initial public offering, Höegh LNG is obligated to offer to the Partnership any floating storage and regasification unit (“FSRU”) or LNG carrier operating under a charter of five or more years.

Höegh LNG is actively pursuing the following projects that are subject to a number of conditions, outside its control, impacting the timing and the ability of such projects to go forward. The Partnership may have the opportunity in the future to acquire the FSRUs listed below, when operating under a charter of five years or more, if one of the following projects is fulfilled:

  • On December 21, 2018, Höegh LNG announced that it had entered a contract with AGL Shipping Pty Ltd. (“AGL”), a subsidiary of AGL Energy Ltd., to provide an FSRU to service AGL’s proposed import facility in Victoria, Australia. The contract is for a period of 10 years and is subject to AGL’s final investment decision by the board of directors of AGL Energy Ltd. for the project and obtaining necessary regulatory and environmental approvals.
  • Höegh LNG has also won exclusivity to provide an FSRU for potential projects for Australian Industrial Energy (“AIE”) at Port Kembla, Australia and for another company in the Asian market. Both projects are dependent on a variety of regulatory approvals or permits as well as final investment decisions.

Höegh LNG has four operating FSRUs, the Höegh Giant (HHI Hull No. 2552), delivered from the shipyard on April 27, 2017, the Höegh Esperanza (HHI Hull No. 2865), delivered from the shipyard on April 5, 2018, Höegh Gannet (HHI Hull No. 2909), delivered from the shipyard on December 6, 2018, and the Höegh Galleon (SHI Hull No. 2220), delivered from the shipyard on August 27, 2019. The Höegh Giant is operating on a contract with Naturgy. The Höegh Esperanza is operating on a contract that commenced on June 7, 2018 with CNOOC Gas & Power Trading and Marketing Ltd. (“CNOOC”). The Höegh Gannet serves on a 12-month LNG carrier contract that commenced in May 2020. The Höegh Galleon operates on an interim LNG carrier contract with Cheniere Marketing International LLP (“Cheniere”) that commenced in September 2019.

Pursuant to the terms of the omnibus agreement, the Partnership will have the right to purchase the Höegh Giant, the Höegh Esperanza, the Höegh Gannet and the Höegh Galleon following acceptance by the respective charterer of the related FSRU under a contract of five years or more, subject to reaching an agreement with Höegh LNG regarding the purchase price.

There can be no assurance that the Partnership will acquire any vessels from Höegh LNG or of the terms upon which any such acquisition may be made.

Presentation of Third Quarter 2020 Results

A presentation will be held today, Thursday, November 19, 2020, at 8:30 A.M. (EST) to discuss financial results for the third quarter of 2020. The results and presentation material will be available for download at http://www.hoeghlngpartners.com.

The presentation will be immediately followed by a Q&A session. Participants will be able to join this presentation using the following details:

a. Webcast


https://www.webcaster4.com/Webcast/Page/942/38684

b. Teleconference

International call:

+1-412-542-4123

US Toll Free call:

+1-855-239-1375

Canada Toll Free call:

+1-855-669-9657

Participants should ask to be joined into the Höegh LNG Partners LP call.

There will be a Q&A session after the presentation. Information on how to ask questions will be given at the beginning of the Q&A session.

For those unable to participate in the conference call, a replay will be available from one hour after the end of the conference call until November 26, 2020.

The replay dial-in numbers are as follows:

International call:

+1-412-317-0088

US Toll Free call:

+1-877-344-7529

Canada Toll Free call:

+1-855-669-9658

Replay passcode:

10149871

Financial Results on Form 6-K

The Partnership has filed a Form 6-K with the SEC with detailed information on the Partnership’s results of operations for the three and nine months ended September 30, 2020, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and unaudited condensed interim consolidated financial statements. The Form 6-K can be viewed on the SEC’s website: http://www.sec.gov and at HMLP’s website: http://www.hoeghlngpartners.com

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements concerning future events and the Partnership’s operations, performance and financial condition. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “believe,” “anticipate,” “expect,” “estimate,” “future,” “project,” “will be,” “will continue,” “will likely result,” “plan,” “intend” or words or phrases of similar meanings. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the Partnership’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: 

  • the effects of outbreaks of pandemic or contagious diseases, including the length and severity of the recent worldwide outbreak of COVID-19, including its impact on the Partnership’s business liquidity, cash flows and operations as well as operations of its customers, suppliers and lenders;
  • market conditions and trends for floating storage and regasification units (“FSRUs”) and liquefied natural gas (“LNG”) carriers, including hire rates, vessel valuations, technological advancements, market preferences and factors affecting supply and demand of LNG, LNG carriers, and FSRUs;
  • the Partnership’s distribution policy and ability to make cash distributions on the Partnership’s units or any increases in the quarterly distributions on the Partnership’s common units;
  • restrictions in the Partnership’s debt agreements and pursuant to local laws on the Partnership’s joint ventures’ and subsidiaries’ ability to make distributions;
  • the Partnership’s joint ventures’ ability to settle the boil-off claim;
  • the ability of Höegh LNG to meet its financial obligations to the Partnership pursuant to the Subsequent Charter, its guarantee and indemnification obligations, including in relation to the boil-off claim;
  • the Partnership’s ability to compete successfully for future chartering opportunities;
  • demand in the FSRU sector or the LNG shipping sector, including demand for the Partnership’s vessels;
  • the Partnership’s ability to purchase additional vessels from Höegh LNG in the future;
  • the Partnership’s ability to integrate and realize the anticipated benefits from acquisitions;
  • the Partnership’s anticipated growth strategies, including the acquisition of vessels;
  • the Partnership’s anticipated receipt of dividends and repayment of indebtedness from subsidiaries and joint ventures;
  • effects of volatility in global prices for crude oil and natural gas;
  • the effect of the worldwide economic environment;
  • turmoil in the global financial markets;
  • fluctuations in currencies and interest rates;
  • general market conditions, including fluctuations in hire rates and vessel values;
  • changes in the Partnership’s operating expenses, including drydocking, on-water class surveys, insurance costs and bunker costs;
  • the Partnership’s ability to comply with financing agreements and the expected effect of restrictions and covenants in such agreements;
  • the financial condition, liquidity and creditworthiness of the Partnership’s existing or future customers and their ability to satisfy their obligations under the Partnership’s contracts;
  • the Partnership’s ability to replace existing borrowings, make additional borrowings and to access public equity and debt capital markets;
  • planned capital expenditures and availability of capital resources to fund capital expenditures;
  • the exercise of purchase options by the Partnership’s customers;
  • the Partnership’s ability to perform under its contracts and maintain long-term relationships with its customers;
  • the Partnership’s ability to leverage Höegh LNG’s relationships and reputation in the shipping industry;
  • the Partnership’s continued ability to enter into long-term, fixed-rate charters and the hire rate thereof;
  • the operating performance of the Partnership’s vessels and any related claims by Total S.A. or other customers;
  • the Partnership’s ability to maximize the use of its vessels, including the redeployment or disposition of vessels no longer under long-term charters;
  • the Partnership’s ability to compete successfully for future chartering and newbuilding opportunities;
  • timely acceptance of the Partnership’s vessels by their charterers;
  • termination dates and extensions of charters;
  • the cost of, and the Partnership’s ability to comply with, governmental regulations and maritime self-regulatory organization standards, as well as standard regulations imposed by its charterers applicable to its business;
  • the availability and cost of low sulfur fuel oil compliant with the International Maritime Organization (“IMO”) sulfur emission limit reductions generally referred to as “IMO 2020” that took effect January 1, 2020 and, absent the installation of expensive scrubbers, reduced the maximum allowable sulfur content for fuel oil used in the marine sector, including the Partnership’s vessels, from 3.5% to 0.5%;
  • economic substance laws and regulations adopted or considered by various jurisdictions of formation or incorporation of the Partnership and certain of its subsidiaries;
  • availability and cost of skilled labor, vessel crews and management, including possible disruptions caused by the COVID-19 outbreak;
  • the number of offhire days and drydocking requirements, including the Partnership’s ability to complete scheduled drydocking on time and within budget;
  • the Partnership’s general and administrative expenses as a publicly traded limited partnership and the Partnership’s fees and expenses payable under the Partnership’s ship management agreements, the technical information and services agreement and the administrative services agreements;
  • the anticipated taxation of the Partnership, its subsidiaries and affiliates and distributions to its unitholders;
  • estimated future maintenance and replacement capital expenditures;
  • the Partnership’s ability to hire or retain key employees;
  • customers’ increasing emphasis on environmental and safety concerns;
  • potential liability from any pending or future litigation;
  • risks inherent in the operation of the Partnership’s vessels including potential disruption due to accidents, political events, piracy or acts by terrorists;
  • future sales of the Partnership’s common units, Series A preferred units and other securities in the public market;
  • the Partnership’s business strategy and other plans and objectives for future operations;
  • the Partnership’s ability to maintain effective internal control over financial reporting and effective disclosure controls and procedures; and
  • other factors listed from time to time in the reports and other documents that the Partnership files with the SEC, including the Partnership’s Annual Report on Form 20-F for the year ended December 31, 2019 and subsequent quarterly reports on Form 6-K.

All forward-looking statements included in this press release are made only as of the date of this press release. New factors emerge from time to time, and it is not possible for the Partnership to predict all of these factors. Further, the Partnership cannot assess the impact of each such factor on its business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. The Partnership does not intend to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any such statement is based. 

 

 

 


HÖEGH LNG PARTNERS LP


UNAUDITED CONDENSED INTERIM CONSOLIDATED


STATEMENTS OF INCOME


(in thousands of U.S. dollars, except per unit amounts)


Three months ended


Nine months ended


September 30,


September 30,


2020


2019


2020


2019


REVENUES

Time charter revenues

$

35,913

$

36,982

$

107,036

$

106,834

Other revenue

64


Total revenues

35,913

36,982

107,036

106,898


OPERATING EXPENSES

Vessel operating expenses

(5,963)

(6,699)

(17,246)

(21,656)

Administrative expenses

(2,455)

(2,228)

(7,037)

(7,076)

Depreciation and amortization

(5,210)

(5,285)

(15,727)

(16,197)


Total operating expenses

(13,628)

(14,212)

(40,010)

(44,929)

Equity in earnings (losses) of joint ventures

5,774

621

2,202

(602)


Operating income (loss)

28,059

23,391

69,228

61,367


FINANCIAL INCOME (EXPENSE), NET

Interest income

135

189

470

685

Interest expense

(6,014)

(6,957)

(18,847)

(20,941)

Gain (loss) on debt extinguishment

1,030

Other items, net

(846)

(854)

(1,980)

(2,660)


Total financial income (expense), net

(6,725)

(7,622)

(20,357)

(21,886)


Income (loss) before tax

21,334

15,769

48,871

39,481

Income tax expense

(1,859)

(2,065)

(4,240)

(5,486)


Net income (loss)

$

19,475

$

13,704

$

44,631

$

33,995

Preferred unitholders’ interest in net income

3,681

3,482

11,017

10,224

Limited partners’ interest in net income (loss)

$

15,794

$

10,222

$

33,614

$

23,771


Basic Earnings per Unit

Common unit public

$

0.46

$

0.30

$

0.97

$

0.68

Common unit Höegh LNG

$

0.49

$

0.57

$

1.05

$

1.36

Subordinated unit Höegh LNG

$

$

$

$

0.52


Diluted earnings per Unit

Common unit public

$

0.46

$

0.29

$

0.97

$

0.68

Common unit Höegh LNG

$

0.49

$

0.57

$

1.05

$

1.36

Subordinated unit Höegh LNG

$

$

$

$

0.52

 

 

 


HÖEGH LNG PARTNERS LP


UNAUDITED CONDENSED INTERIM CONSOLIDATED


BALANCE SHEETS


(in thousands of U.S. dollars)


As of


September 30,


December 31,


2020


2019


ASSETS


Current assets

Cash and cash equivalents

$

25,048

$

39,126

Restricted cash

6,524

8,066

Trade receivables

4,522

735

Amounts due from affiliates

3,658

4,296

Inventory

463

Current portion of net investment in financing lease

4,861

4,551

Prepaid expenses and other receivables

3,133

2,534


Total current assets

47,746

59,771


Long-term assets

Restricted cash

12,210

12,627

Accumulated earnings of joint ventures

5,472

3,270

Advances to joint ventures

4,069

3,831

Vessels, net of accumulated depreciation

624,825

640,431

Other equipment

83

256

Intangibles and goodwill

14,750

17,108

Net investment in financing lease

270,572

274,353

Long-term deferred tax asset

253

217

Other long-term assets

848

936


Total long-term assets

933,082

953,029


Total assets

$

980,828

$

1,012,800

 

 


HÖEGH LNG PARTNERS LP


UNAUDITED CONDENSED INTERIM CONSOLIDATED


BALANCE SHEETS


(in thousands of U.S. dollars)


As of


September 30,


December 31,


2020


2019


LIABILITIES AND EQUITY


Current liabilities

Current portion of long-term debt

$

44,660

$

44,660

Trade payables

269

533

Amounts due to owners and affiliates

2,427

2,513

Value added and withholding tax liability

782

1,476

Derivative instruments

7,204

2,907

Accrued liabilities and other payables

8,119

11,164


Total current liabilities

63,461

63,253


Long-term liabilities

Long-term debt

380,544

412,301

Revolving credit facility due to owners and affiliates

11,292

8,792

Derivative instruments

21,713

12,028

Long-term tax liability

2,572

2,283

Long-term deferred tax liability

14,127

12,549

Other long-term liabilities

53

84


Total long-term liabilities

430,301

448,037


Total liabilities

493,762

511,290


EQUITY

8.75% Series A preferred units

6,719,382 units issued and outstanding at September 30, 2020 and

6,625,590 units issued and outstanding at December 31, 2019

166,887

164,482

Common units public

18,040,432 units issued and outstanding at September 30, 2020 and

18,028,786 units issued and outstanding at December 31, 2019

308,971

315,176

Common units Höegh LNG

15,257,498 units issued and outstanding at September 30, 2020 and

December 31, 2019

43,188

39,795

Accumulated other comprehensive income (loss)

(31,980)

(17,943)


Total partners’ capital

487,066

501,510


Total equity

487,066

501,510


Total liabilities and equity

$

980,828

$

1,012,800

 

 


HÖEGH LNG PARTNERS LP


UNAUDITED CONDENSED INTERIM CONSOLIDATED


STATEMENTS OF CASH FLOWS


(in thousands of U.S. dollars)


Three months ended


September 30,


2020


2019


OPERATING ACTIVITIES

Net income (loss)

$

19,475

$

13,704

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

  Depreciation and amortization

5,210

5,285

  Equity in losses (earnings) of joint ventures

(5,774)

(621)

  Changes in accrued interest income on advances to joint ventures

(82)

(76)

  Amortization of deferred debt issuance cost and fair value of debt assumed

567

631

  Amortization in revenue for above market contract and extension

694

916

  Expenditure for drydocking

(284)

  Changes in accrued interest expense

(147)

54

  Receipts from repayment of principal on financing lease

1,150

1,053

  Unrealized foreign exchange losses (gains)

90

55

  Unrealized loss (gain) on derivative instruments

24

14

  Non-cash revenue: tax paid directly by charterer

(215)

(214)

  Non-cash income tax expense: tax paid directly by charterer

215

214

  Deferred tax expense and provision for tax uncertainty

809

932

  Issuance of units for Board of Directors’ fees

128

39

  Other adjustments

(85)

167

  Changes in working capital:

  Trade receivables

(261)

(3)

  Inventory

(2)

  Prepaid expenses and other receivables

174

(753)

  Trade payables

(136)

87

  Amounts due to owners and affiliates

843

(2,678)

  Value added and withholding tax liability

(250)

1,002

  Accrued liabilities and other payables

379

(91)

  Net cash provided by (used in) operating activities

$

22,808

$

19,431


INVESTING ACTIVITIES

  Expenditure for vessel and other equipment

(129)


  Net cash provided by (used in) investing activities

$

$

(129)

 

 


HÖEGH LNG PARTNERS LP


UNAUDITED CONDENSED INTERIM CONSOLIDATED


STATEMENTS OF CASH FLOWS


(in thousands of U.S. dollars)


Three months ended


September 30,


2020


2019


FINANCING ACTIVITIES

Proceeds from long-term debt

$

$

48,300

Proceeds from revolving credit facility due to owners and affiliates

6,600

Repayment of long-term debt

(11,165)

(11,165)

Repayment of revolving credit facility due to owners and affiliates

(34,000)

Repayment of customer loan for funding of value added liability on import

(438)

Net proceeds from issuance of 8.75% Series A preferred units

268

1,403

Cash distributions to limited partners and preferred unitholders

(18,713)

(18,417)


Net cash provided by (used in) financing activities

(23,010)

(14,317)

Increase (decrease) in cash, cash equivalents and restricted cash

(202)

4,985

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(29)

(52)

Cash, cash equivalents and restricted cash, beginning of period

44,013

48,035

Cash, cash equivalents and restricted cash, end of period

$

43,782

$

52,968

 

HÖEGH LNG PARTNERS LP

UNAUDITED SEGMENT INFORMATION FOR THE QUARTER ENDED SEPTEMBER 30, 2020 AND 2019

(in thousands of U.S. dollars)

Segment information

There are two operating segments. The segment profit measure is Segment EBITDA, which is defined as earnings before interest, taxes, depreciation, amortization and impairment, and other financial items (gain (loss) on debt extinguishment, gain (loss) on derivative instruments and other items, net). Segment EBITDA is reconciled to operating income and net income in the segment presentation below. The two segments are “Majority held FSRUs” and “Joint venture FSRUs.” In addition, unallocated corporate costs, interest income from advances to joint ventures and interest expense related to the outstanding balances on the $85 million revolving credit facility and the $385 million facility are included in “Other.”

For the three months ended September 30, 2020 and 2019, Majority held FSRUs includes the financing lease related to the PGN FSRU Lampung and the operating leases related to the Höegh Gallant and the Höegh Grace.

For the three months ended September 30, 2020 and 2019, Joint venture FSRUs include two 50% owned FSRUs, the Neptune and the Cape Ann, that operate under long term time charters with one charterer.

The accounting policies applied to the segments are the same as those applied in the consolidated financial statements, except that i) Joint venture FSRUs are presented under the proportional consolidation method for the segment note to the Partnership’s financial statements and under equity accounting for the consolidated financial statements and ii) internal interest income and interest expense between the Partnership’s subsidiaries that eliminate in consolidation are not included in the segment columns for the other financial income (expense), net line. Under the proportional consolidation method, 50% of the Joint venture FSRUs’ revenues, expenses and assets are reflected in the segment information. Management monitors the results of operations of joint ventures under the proportional consolidation method and not the equity method of accounting.

 


HÖEGH LNG PARTNERS LP


UNAUDITED SEGMENT INFORMATION FOR THE QUARTER ENDED SEPTEMBER 30, 2020


(in thousands of U.S. dollars) 


Three months ended September 30, 2020


Joint venture


Majority


FSRUs


Total


held


(proportional


Segment


Elimin-


Consolidated


FSRUs


consolidation)


Other


reporting


ations


Reporting

Time charter revenues

$

35,913

10,896

46,809

(10,896)

(1)

$

35,913


Total revenues

35,913

10,896

46,809

35,913

Operating expenses

(6,831)

(1,957)

(1,587)

(10,375)

1,957

(1)

(8,418)

Equity in earnings (losses) of joint ventures

5,774

(1)

5,774


Segment EBITDA


29,082


8,939


(1,587)


36,434

Depreciation, amortization and impairment

(5,210)

(2,490)

(7,700)

2,490

(1)

(5,210)


Operating income (loss)

23,872

6,449

(1,587)

28,734

28,059

Gain (loss) on derivative instruments

2,226

2,226

(2,226)

(1)

Other financial income (expense), net

(2,415)

(2,901)

(4,310)

(9,626)

2,901

(1)

(6,725)


Income (loss) before tax

21,457

5,774

(5,897)

21,334

21,334

Income tax benefit (expense)

(1,859)

(1,859)

(1,859)


Net income (loss)

$

19,598

5,774

(5,897)

19,475

$

19,475

Preferred unitholders’ interest in net income

3,681

(2)

3,681

Limited partners’ interest in net income (loss)

$

19,598

5,774

(5,897)

19,475

(3,681)

(2)

$

15,794

(1)

Eliminations reverse each of the income statement line items of the proportional amounts for Joint venture FSRUs and record the Partnership’s share of the Joint venture FSRUs net income (loss) to Equity in earnings (losses) of joint ventures.

(2)

Allocates the preferred unitholders’ interest in net income to the preferred unitholders.

 

 


HÖEGH LNG PARTNERS LP


UNAUDITED SEGMENT INFORMATION FOR THE QUARTER ENDED SEPTEMBER 30, 2019


(In thousands of U.S. dollars)


Three months ended September 30, 2019


Joint venture


Majority


FSRUs


Total


held


(proportional


Segment


Elimin-


Consolidated


FSRUs


consolidation)


Other


reporting


ations


Reporting

Time charter revenues

$

36,982

10,820

47,802

(10,820)

(1)

$

36,982


Total revenues

36,982

10,820

47,802

36,982

Operating expenses

(7,490)

(2,478)

(1,437)

(11,405)

2,478

(1)

(8,927)

Equity in earnings (losses) of joint ventures

621

(1)

621


Segment EBITDA


29,492


8,342


(1,437)


36,397

Depreciation, amortization and impairment

(5,285)

(2,528)

(7,813)

2,528

(1)

(5,285)


Operating income (loss)

24,207

5,814

(1,437)

28,584

23,391

Gain (loss) on derivative instruments

(2,165)

(2,165)

2,165

(1)

Other financial income (expense), net

(2,837)

(3,028)

(4,785)

(10,650)

3,028

(1)

(7,622)


Income (loss) before tax

21,370

621

(6,222)

15,769

15,769

Income tax expense

(2,065)

(2,065)

(2,065)


Net income (loss)

$

19,305

621

(6,222)

13,704

$

13,704

Preferred unitholders’ interest in net income

3,482

(2)

3,482

Limited partners’ interest in net income (loss)

$

19,305

621

(6,222)

13,704

(3,482)

(2)

$

10,222

(1)

Eliminations reverse each of the income statement line items of the proportional amounts for Joint venture FSRUs and record the Partnership’s share of the Joint venture FSRUs net income (loss) to Equity in earnings (losses) of joint ventures.

(2)

Allocates the preferred unitholders’ interest in net income to the preferred unitholders.

 

 


HÖEGH LNG PARTNERS LP


UNAUDITED SCHEDULE OF FINANCIAL INCOME AND EXPENSE


(In thousands of U.S. dollars)

The following table includes the financial income (expense), net for the three months ended September 30, 2020 and 2019. 


Three months ended


September 30,


(in thousands of U.S. dollars)


2020


2019


Interest income

$

135

$

189


Interest expense:

Interest expense

(5,412)

(6,240)

Commitment fees

(35)

(86)

Amortization of debt issuance cost and fair value of debt assumed

(567)

(631)


Total interest expense

(6,014)

(6,957)


Other items, net:

Unrealized foreign exchange gain (loss)

(90)

(55)

Realized foreign exchange gain (loss)

(67)

(50)

Bank charges, fees and other

(93)

(110)

Withholding tax on interest expense and other

(596)

(639)


Total other items, net

(846)

(854)

Total financial income (expense), net

$

(6,725)

$

(7,622)

 

Appendix A: Segment EBITDA

Non-GAAP Financial Measures

Segment EBITDA. EBITDA is defined as earnings before interest, depreciation and amortization and taxes. Segment EBITDA is defined as earnings before interest, taxes, depreciation, amortization, impairment and other financial items. Other financial items consist of gain (loss) on debt extinguishment, gain (loss) on derivative instruments and other items, net (including foreign exchange gains and losses and withholding tax on interest expenses). Segment EBITDA is used as a supplemental financial measure by management and external users of financial statements, such as the Partnership’s lenders, to assess its financial and operating performance. The Partnership believes that Segment EBITDA assists its management and investors by increasing the comparability of its performance from period to period and against the performance of other companies in the industry that provide Segment EBITDA information. This increased comparability is achieved by excluding the potentially disparate effects between periods or companies of interest, depreciation, amortization, impairment, taxes, and other financial items, which items are affected by various and possibly changing financing methods, capital structure and historical cost basis and which items may significantly affect net income between periods. The Partnership believes that including Segment EBITDA as a financial and operating measure benefits investor in (a) selecting between investing in it and other investment alternatives and (b) monitoring its ongoing financial and operational strength in assessing whether to continue to hold common units or preferred units. Segment EBITDA is a non-GAAP financial measure and should not be considered an alternative to net income, operating income or any other measure of financial performance presented in accordance with U.S. GAAP. Segment EBITDA excludes some, but not all, items that affect net income, and these measures may vary among other companies. Therefore, Segment EBITDA as presented below may not be comparable to similarly titled measures of other companies. The following tables reconcile Segment EBITDA for each of the segments and the Partnership as a whole to net income (loss), the comparable U.S. GAAP financial measure, for the periods presented:


Three months ended September 30, 2020


Joint venture


Majority


FSRUs


Total


held


(proportional


Segment


Elimin-


Consolidated


(in thousands of U.S. dollars)


FSRUs


consolidation)


Other


reporting


ations(1)


reporting


Reconciliation to net income (loss)

Net income (loss)

$

19,598

5,774

(5,897)

19,475

$

19,475

(3)

Interest income

(52)

(83)

(135)

(135)

Interest expense

1,807

2,895

4,207

8,909

(2,895)

(4)

6,014

Depreciation and amortization

5,210

2,490

7,700

(2,490)

(5)

5,210

Other financial items (2)

660

(2,220)

186

(1,374)

2,220

(6)

846

Income tax (benefit) expense

1,859

1,859

1,859


Equity in earnings of JVs: Interest (income) expense, net

2,895

(4)

2,895


Equity in earnings of JVs: Depreciation and amortization

2,490

(5)

2,490


Equity in earnings of JVs: Other financial items (2)

(2,220)

(6)

(2,220)


Segment EBITDA


$


29,082


8,939


(1,587)


36,434


$


36,434

 


Three months ended September 30, 2019


Joint venture


Majority


FSRUs


Total


held


(proportional


Segment


Elimin-


Consolidated


(in thousands of U.S. dollars)


FSRUs


consolidation)


Other


reporting


ations(1)


reporting


Reconciliation to net income (loss)

Net income (loss)

$

19,305

621

(6,222)

13,704

$

13,704

(3)

Interest income

(66)

(107)

(123)

(296)

107

(4)

(189)

Interest expense

2,105

3,133

4,852

10,090

(3,133)

(4)

6,957

Depreciation, and amortization and impairment

5,285

2,528

7,813

(2,528)

(5)

5,285

Other financial items (2)

798

2,167

56

3,021

(2,167)

(6)

854

Income tax (benefit) expense

2,065

2,065

2,065


Equity in earnings of JVs: Interest (income) expense, net

3,026

3,026


Equity in earnings of JVs: Depreciation and amortization

2,528

(5)

2,528


Equity in earnings of JVs: Other financial items (2)

2,167

(6)

2,167


Segment EBITDA


$


29,492


8,342


(1,437)


36,397


$


36,397

(1)

Eliminations reverse each of the income statement reconciling line items of the proportional amounts for Joint venture FSRUs that are reflected in the consolidated net income for the Partnership’s share of the Joint venture FSRUs net income (loss) on the Equity in earnings (losses) of joint ventures line item in the consolidated income statement. Separate adjustments from the consolidated net income to Segment EBITDA for the Partnership’s share of the Joint venture FSRUs are included in the reconciliation lines starting with “Equity in earnings of JVs.

(2)

Other financial income consists of gains and losses on derivative financial instruments and other items, net including foreign exchange gains or losses and withholding tax on interest expense.

(3)

There is no adjustment between net income for Total Segment reporting and the Consolidated reporting because the net income under the proportional consolidation and equity method of accounting is the same.

(4)

Interest income and interest expense for the Joint venture FSRUs is eliminated from the Total Segment reporting to agree to the interest income and interest expense in the Consolidated reporting and reflected as a separate adjustment to the equity accounting on the line Equity in earnings of JVs: Interest (income) expense for the Consolidated reporting.

(5)

Depreciation, amortization and impairment for the Joint venture FSRUs is eliminated from the Total Segment reporting to agree to the depreciation and amortization in the Consolidated reporting and reflected as a separate adjustment to the equity accounting on the line Equity in earnings of JVs: Depreciation and amortization for the Consolidated reporting.

(6)

Other financial items for the Joint venture FSRUs is eliminated from the Segment reporting to agree to the Other financial items in the Consolidated reporting and reflected as a separate adjustment to the equity accounting on the line Equity in earnings of JVs: Other financial items for the Consolidated reporting.

 

Appendix B: Distributable Cash Flow

Distributable cash flow represents Segment EBITDA adjusted for cash collections on principal payments on the financing lease, amortization in revenues for above market contracts less non-cash revenue: tax paid directly by charterer, amortization of deferred revenues for the joint ventures, interest income‎, interest expense less amortization of debt issuance cost, amortization and gain on cash flow hedges included in interest expense and proceeds from settlement of derivatives, other items (net), unrealized foreign exchange losses (gains), current income tax benefit (expense), net of uncertain tax position less non-cash income tax: tax paid directly by charterer, and other adjustments such as indemnification paid or to be paid by Höegh LNG for legal expenses related to the boil-off claim, non-budgeted expenses or losses, or prior period indemnifications refunded to, or to be refunded to, Höegh LNG for amounts recovered from insurance or the charterer, distributions on the Series A preferred units and estimated maintenance and replacement capital expenditures. Cash collections on the financing lease investment with respect to the PGN FSRU Lampung consist of the difference between the payments under time charter and the revenues recognized as a financing lease (representing the payment of the principal recorded as a receivable). Amortization in revenues for above market contracts consist of the non-cash amortization of the intangible for the above market time charter contract related to the acquisitions of the Höegh Gallant and Höegh Grace. Amortization of deferred revenues for the joint ventures accounted for under the equity method consist of non-cash amortization to revenues of charterer payments for modifications and drydocking to the vessels. Non-cash revenue: tax paid directly by charterer and non-cash income tax: tax paid directly by charterer consists of certain taxes paid by the charterer directly to the Colombian tax authorities on behalf of the Partnership’s subsidiaries which is recorded as a component of time charter revenues and current income tax expenses. Estimated maintenance and replacement capital expenditures, including estimated expenditures for drydocking, represent capital expenditures required to maintain over the long-term the operating capacity of, or the revenue generated by, the Partnership’s capital assets.

Distributable cash flow is presented starting with Segment EBITDA taken from the total segment reporting using the proportional consolidation method for the Partnership’s 50% interests in the joint ventures as shown in Appendix A. Therefore, the adjustments to Segment EBITDA include the Partnership’s share of the joint venture’s adjustments. The Partnership believes distributable cash flow is an important liquidity measure used by management and investors in publicly traded partnerships to compare cash generating performance of the Partnership’ cash generating assets from period to period by adjusting for cash and non-cash items that could potentially have a disparate effect between periods, and to compare the cash generating performance for specific periods to the cash distributions (if any) that are expected to be paid to limited partners. The Partnership also believes distributable cash flow benefits investors in comparing its cash generating performance to other companies that account for time charters as operating leases rather than financial leases, or that do not have non-cash amortization of intangibles or deferred revenue. Distributable cash flow is a non-GAAP liquidity measure and should not be considered as an alternative to net cash provided by operating activities, or any other measure of the Partnership’s liquidity or cash flows calculated in accordance with GAAP. Distributable cash flow excludes some, but not all, items that affect net cash provided by operating activities and the measures may vary among companies. For example, distributable cash flow does not reflect changes in working capital balances. Distributable cash flow also includes some items that do not affect net cash provided by operating activities. Therefore, distributable cash flow may not be comparable to similarly titled measures of other companies. Distributable cash flow is not the same measure as available cash or operating surplus, both of which are defined by the Partnership’s partnership agreement. The first table below reconciles distributable cash flow to Segment EBITDA, which is reconciled to net income, the most directly comparable GAAP measure for Segment EBITDA, in Appendix A. Refer to Appendix A for the definition of Segment EBITDA. The second table below reconciles distributable cash flow to net cash provided by operating activities, the most directly comparable GAAP measure for liquidity. 

 


Three months ended


(in thousands of U.S. dollars)


September 30, 2020


Segment EBITDA

$

36,434

Cash collection/Principal payment on financing lease

1,150

Amortization in revenues for above market contracts

694

Non-cash revenue: Tax paid directly by charterer

(215)


Equity in earnings of JVs: Amortization of deferred revenue

(682)

Interest income (1)

135

Interest expense (1)

(8,909)

Amortization of debt issuance cost (1)

608

Amortization and gain on cash flow hedges included in interest expense

24

Other items, net

(852)

Unrealized foreign exchange losses (gains)

90

Current income tax benefit (expense), net of uncertain tax position

(1,050)

Non-cash income tax: Tax paid directly by charterer

215


Other adjustments:

Distributions relating to Series A preferred units (2)

(3,681)

Estimated maintenance and replacement capital expenditures

(5,350)


Distributable cash flow

$

18,611

 


Reconciliation of distributable cash flows to net cash provided by (used in) operating activities


Three months ended


(in thousands of U.S. dollars)


September 30, 2020

Distributable cash flow

$

18,611

Estimated maintenance and replacement capital expenditures

5,350

Distributions relating to Series A preferred units (2)

3,681


Equity in earnings of JVs: Amortization of deferred revenue

682


Equity in earnings of JVs: Amortization of debt issuance cost

(40)


Equity in earnings of JVs: Depreciation, amortization and impairment

(2,490)


Equity in earnings of JVs: Gain (loss) on derivative instruments

2,226

Equity in losses (earnings) of joint ventures

(5,774)

Changes in accrued interest expense and interest income

(229)

Other adjustments

42

Changes in working capital

749


Net cash provided by (used in) operating activities


$


22,808

(1)

The Partnership’s interest in the joint ventures’ interest expense and amortization of debt issuance cost is $2,895 and $40, respectively

(2)

Represents distributions payable on the Series A preferred units related to the three months ended September 30, 2020

 

 

Media contact:
The IGB Group, Bryan Degnan, +1 (646) 673-9701 / Leon Berman, +1 (212) 477-8438
Knut Johan Arnholdt, VP IR and Strategy, +47 922 59 131
www.hoeghlngpartners.com

 

Cision View original content:http://www.prnewswire.com/news-releases/hoegh-lng-partners-lp-reports-financial-results-for-the-quarter-ended-september-30-2020-301176671.html

SOURCE Hoegh LNG Partners LP

PermRock Royalty TrustDeclares Monthly Cash Distribution

PR Newswire

FORT WORTH, Texas, Nov. 19, 2020 /PRNewswire/ — PermRock Royalty Trust (NYSE:PRT) (the “Trust”) today declared a monthly cash distribution to record holders of its trust units representing beneficial interests in the Trust (“Trust Units”) as of November 30, 2020 and payable on December 14, 2020 in the amount of $247,982.07  ($0.020383 per Trust Unit), based principally upon production during the month of September 2020.

The following table displays underlying oil and natural gas sales volumes and average received wellhead prices attributable to the current and prior month net profits interest calculations:


Underlying Sales Volumes


Average Price


Oil


Natural Gas


Oil


(per Bbl)


Natural Gas


(per Mcf)


Bbls


Bbls/D


Mcf


Mcf/D

Current Month

32,945

1,098

52,370

1,746

$37.03

$2.01

Prior Month

35,896

1,158

52,804

1,703

$39.38

$2.03

Oil cash receipts for the properties underlying the Trust totaled $1.22 million for the current month, a decrease of $0.19 million from the prior month’s distribution period.  This decrease was due to a decrease in sales volumes and oil prices.  

Natural gas cash receipts for the properties underlying the Trust totaled $0.11 million for the current month, which is unchanged from the prior month’s distribution period.

Total direct operating expenses, including marketing, lease operating expenses and workover expenses, were $0.56 million reflecting a $0.06 million increase from the prior month. Severance and ad valorem taxes were $0.17 million.

Capital expenditures were $0.21 million in the current month reflecting a $0.13 million decrease from the prior month due to a reduction in re-entry work in the Kingdom Abo operating area.  Boaz Energy informed the Trust that this month’s net profits calculation included $80,000 net to the Trust of funds reserved by Boaz Energy to cover future capital obligations and expenses. 

About PermRock Royalty Trust

PermRock Royalty Trust is a Delaware statutory trust formed by Boaz Energy II, LLC (“Boaz Energy”) to own a net profits interest representing the right to receive 80% of the net profits from the sale of oil and natural gas production from certain properties owned by Boaz Energy in the Permian Basin of West Texas. For more information on PermRock Royalty Trust, please visit our website at www.permrock.com.

Cautionary Statement Concerning Forward-Looking Statements

Certain statements contained in this press release constitute “forward-looking statements.” These forward-looking statements represent the Trust’s and Boaz Energy’s expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements include the amount and date of any anticipated distribution to unitholders, future cash retentions, advancements or recoupments from distributions, and statements regarding Boaz Energy’s operations and the resulting impact on the computation of the Trust’s net profits. The amount of cash received or expected to be received by the Trust (and its ability to pay distributions) has been and will continue to be directly affected by the volatility in commodity prices, which have declined since the beginning of 2020 in response to oversupply and the economic effects of the COVID-19 pandemic. Further, continued low oil and natural gas prices may result in no distributions to unitholders in certain periods. Other important factors that could cause actual results to differ materially from those projected in the forward-looking statements include expenses of the Trust and reserves for anticipated future expenses, uncertainties in estimating the cost of drilling activities and risks associated with drilling and operating oil and natural gas wells.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, the Trust does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for the Trust to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in the Trust’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2020 and other public filings filed with the SEC. The risk factors and other factors noted in the Trust’s public filings with the SEC could cause its actual results to differ materially from those contained in any forward-looking statement. The Trust’s filed reports are or will be available over the Internet at the SEC’s website at http://www.sec.gov.

Contact:

PermRock Royalty Trust

Simmons Bank, Trustee

Lee Ann Anderson, Senior Vice President

Toll-free: (855) 588-7839

Fax: (817) 298-5579

Website:  www.permrock.com

e-mail:  [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/permrock-royalty-trustdeclares-monthly-cash-distribution-301176821.html

SOURCE PermRock Royalty Trust

Amesite Inc. Announces Successful Completion of Pilot Learning Program with Ford Motor Company

PR Newswire

ANN ARBOR, Mich., Nov. 19, 2020 /PRNewswire/ — AmesiteInc. (Nasdaq: AMST), an artificial intelligence software company providing online learning ecosystems for business, higher education, and K-12, announced today it has successfully completed delivery of a pilot learning program for the Ford Motor Company, building content and offering the experience on its advanced platform.

“Our successful pilot with a diverse, global cohort of full-time professionals at Ford showed that the online learning delivered on our AI-driven platform was convenient and beneficial,” said Amesite Founder and CEO Dr. Ann Marie Sastry. “A survey of participants showed that their interest in subject matter deepened, that the fresh content delivered via Amesite’s AI helped them relate course material to real-world events, and that the quality of customer service and instruction were high.”

Amesite creates outstanding learning experiences, delivered on its advanced platform, providing a positive impact for employees. Using AI to provide fresh content creates important context for learning. Coupled with outstanding services, these experiences deepen professionals’ interest in subjects important to their company’s goals, and spur creative ways in which to execute on new practices.


About Amesite Inc.

Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for K-12, college, university and business education and upskilling. Amesite-offered courses and programs are branded to our customers.  Amesite uses artificial intelligence technologies to provide customized environments for learners, easy-to-manage interfaces for instructors, and greater accessibility for learners in the US education market and beyond.  The Company leverages existing institutional infrastructures, adding mass customization and cutting-edge technology to provide cost-effective, scalable and engaging experiences for learners anywhere. For more information, visit https://amesite.com.


Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company’s planned online machine learning platform, the Company’s business plans, any future commercialization of the Company’s online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact: Robert Busweiler[email protected] – 631.379.6454

Cision View original content:http://www.prnewswire.com/news-releases/amesite-inc-announces-successful-completion-of-pilot-learning-program-with-ford-motor-company-301176589.html

SOURCE Amesite Inc.

Western Midstream Releases Inaugural ESG Report

PR Newswire

HOUSTON, Nov. 19, 2020 /PRNewswire/ — Today Western Midstream Partners, LP (NYSE: WES) (“WES” or “Western Midstream”) announced the release of its inaugural Environmental, Social and Governance (ESG) Report.

“Western Midstream’s first ESG Report exemplifies our employees’ dedication to cultivating a culture of strong corporate responsibility while safely and responsibly managing our daily operations,” said President, Chief Executive Officer, and Chief Financial Officer, Michael Ure. “We’re proud of the progress we’ve made in reducing our environmental footprint and contributing positively to our local communities, workforce, and other stakeholders. Now, as we transition to a stand-alone midstream business, it’s imperative that we introduce stakeholders to our approach to ESG issues and our successes to date.”

As detailed in the report, Western Midstream’s ESG strategy focuses on three pillars: supporting sustainable environments, focusing on people, and operating responsibly. Ure continued, “These pillars are rooted in our operating philosophy as demonstrated by our direct-to-wellhead pipeline infrastructure and design of our facilities, which significantly reduces release risks, eliminates storage equipment at the well-site, and reduces emissions. Additionally, we play an important role in delivering natural gas, a lower-emission bridge fuel that will assist in the global transition to cleaner energy sources. We look forward to strengthening our ESG performance and reporting as we further enhance the achievements accomplished to date.”

To read the report and learn more about our ESG efforts, please visit the Sustainability section of our website at www.westernmidstream.com.

ABOUT WESTERN MIDSTREAM
Western Midstream Partners, LP (“WES”) is a Delaware master limited partnership formed to acquire, own, develop, and operate midstream assets. With midstream assets located in the Rocky Mountains, North-central Pennsylvania, Texas, and New Mexico, WES is engaged in the business of gathering, compressing, treating, processing, and transporting natural gas; gathering, stabilizing, and transporting condensate, natural-gas liquids, and crude oil; and gathering and disposing of produced water for its customers. In its capacity as a natural-gas processor, WES also buys and sells natural gas, natural-gas liquids, and condensate on behalf of itself and as an agent for its customers under certain contracts. For more information about Western Midstream Partners, LP, please visit www.westernmidstream.com.

This news release contains forward-looking statements. WES’s management believes that its expectations are based on reasonable assumptions. No assurance, however, can be given that such expectations will prove correct. A number of factors could cause actual results to differ materially from the expectations expressed in this news release. These factors include our ability to strengthen WES’s ESG performance and reporting, and the other factors described in the “Risk Factors” section of WES’s most-recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission and other public filings and press releases. WES undertakes no obligation to publicly update or revise any forward-looking statements.

WESTERN MIDSTREAM CONTACTS

Kristen Shults

Vice President, Investor Relations and Communications
[email protected] 
832.636.6000

Abby Dempsey

Investor Relations Supervisor
[email protected] 
832.636.6000

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/western-midstream-releases-inaugural-esg-report-301176698.html

SOURCE Western Midstream Partners, LP